Health at A Glance Asia Pacific 2022
Health at A Glance Asia Pacific 2022
Health at A Glance Asia Pacific 2022
Asia/Pacific 2022
MEASURING PROGRESS TOWARDS UNIVERSAL
HEALTH COVERAGE
Health at a Glance:
Asia/Pacific
2022
This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over
any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.
The names and representation of countries and territories used in this joint publication follow the practice of the OECD.
Photo credits: Cover © Meawpong3405/Shutterstock.com; © Richard Clarke/espion/Catherine Yeulet/Jason Hamel/Kim Gunkel/David Gunn/
iStockphoto.com.
The use of this work, whether digital or print, is governed by the Terms and Conditions to be found at https://www.oecd.org/termsandconditions.
3
Foreword
The COVID-19 pandemic has had a significant and lasting impact on health systems and economies in
most countries around the world, including those in the Asia-Pacific region. Since January 2020,
over 1 million people have died due to the COVID-19 pandemic in the Asia-Pacific region, and more than
80 million lost their jobs in 2020. Amid the recovery is under way, it is critical that stakeholders identify
lessons learned, while at the same time leveraging heightened awareness of the importance of health
resilience and preparedness to propel investment, commitment, and action towards building resilient health
systems that are adequately prepared for the complex health challenges of the future.
In response to the pandemic, most Asia-Pacific countries introduced rapid and far-reaching measures to
protect people’s health and livelihoods, ranging from effective contact tracing strategies, to smart
containment measures, and later to successful vaccination campaigns. However, the crisis has also
exposed underlying health system shortcomings and social and economic inequities often further
exacerbating them. As this report outlines, limited access to essential health care services, in particular for
disadvantaged groups such as women living in low-income households or rural areas, and high levels of
out-of-pocket and catastrophic health spending remain significant issues in Asia-Pacific.
To remedy these and other challenges, universal health coverage ensures that all people can access
quality health services, without financial hardship. It is the foundation of a resilient health system, and
ensures that when acute events occur, essential health services can be maintained. Building equitable and
resilient health systems not only protects people’s lives, especially in times of crisis, but also pave the way
towards inclusive recovery, social justice and sustainable development.
The COVID-19 pandemic has clearly demonstrated that when health is at risk, everything is at risk. This
suggests that ensuring greater resilience and preparedness to shocks – and the required investment to
achieve these goals – should be a key element of governments’ overall commitment to sustainable social
and economic development.
Only with significant and sustained financial investment and political commitment can countries mobilise
the whole-of-government capacity needed to tackle the increasingly complex health challenges of our time.
In the months, years and decades ahead, key priorities include investing in innovative health and social
care service delivery models, including patient-centred and integrated primary health care; adopting digital
health interventions; and creating healthy environments and lifestyles to promote healthy ageing.
Given that health is intricately linked to social, economic and cultural life, delivering this agenda and
working towards more just and equitable societies and health systems requires a multidisciplinary, cross-
sectorial and collaborative approach. Ultimately, investments to achieve quality and accessible health care
for all, without financial hardship, are investments in overall economic and social development that will
translate into healthier, more resilient and cohesive societies that are future-ready.
Table of contents
Foreword 3
Reader’s guide 8
Acronyms and abbreviations 12
Executive summary 13
1 Country and territory dashboards 14
Health status 15
Risk factors 16
Quality of care 17
Health care resources 18
3 Health status 46
Life expectancy at birth and survival rate to age 65 47
Neonatal mortality 50
Infant mortality 53
Under age 5 mortality 55
Mortality from all causes 58
Mortality from cardiovascular disease 61
Mortality from cancer 64
Mortality from injuries 67
Maternal mortality 70
Tuberculosis 73
HIV/AIDS 76
Malaria 78
Diabetes 81
Ageing 83
4 Determinants of health 86
Family planning 87
Infant and young child feeding 90
Child malnutrition (including undernutrition and overweight) 93
Water and sanitation 96
Tobacco 99
https://www.facebook.com/theOECD
https://www.linkedin.com/company/organisation-eco-cooperation-
development-organisation-cooperation-developpement-eco/
https://www.youtube.com/user/OECDiLibrary
https://www.oecd.org/newsletters/
This book has... A service that delivers Excel® files from the printed page!
Reader’s guide
Health at a Glance: Asia/Pacific presents a set of key indicators on health and health systems for 27 Asia-
Pacific countries and territories. It builds on the format used in previous editions of Health at a Glance to
present comparable data on health status and its determinants, health care resources and utilisation,
health care expenditure and financing and health care quality.
This publication was prepared jointly by the WHO Regional Office for the Western Pacific (WHO/WPRO),
the WHO Regional Office for South-East Asia (WHO/SEARO), the OECD Health Division and the
OECD/Korea Policy Centre, under the co-ordination of Luca Lorenzoni from the OECD Health Division.
Chapter 1 and Chapter 2 were prepared by Luca Lorenzoni, Yoshiaki Hori, Gabriel Di Paolantonio and
Tom Raitzik Zonenschein from the OECD Health Division, with support from Ayodele Akinnawo,
Eriko Anzai, Benjamin Bayutas, Emma Callon, Mengjuan Duan, Kareena Hundal, Chung Won Lee,
Ji Young Lee, Kayla Mae Mariano, Tamano Matsui, Sangjun Moon, Manilay Phengxay,
Ariuntuya Ochirpurev, Babatunde Olowokure, Jinho Shin, Alpha Grace Tabanao, Martin Vandendyck,
Ding Wang, Xiaojun Wang, Tracy Yuen, Masahiro Zakoji, and Angel Grace Zorilla from WHO/WPRO.
Chapter 3, Chapter 4 and Chapter 5 were prepared by Luca Lorenzoni, Gabriel Di Paolantonio and
Tom Raitzik Zonenschein from the OECD Health Division, with support from Robert Ryan Arciaga,
Sahar Bajis, Mengjuan Duan, Kiyohiko Izumi, James Kelley, April Siwon Lee, Virginia Macdonald,
Ada Moadsiri, Fukushi Morishita, Jinho Shin, Alpha Grace Tabanao, Josaia Tiko, Juliawati Untoro,
Martin Vandendyck, Delgermaa Vanya, Manami Yanagawa, Tracy Yuen, and Masahiro Zakoji from
WHO/WPRO. Chapter 6 was written by Luca Lorenzoni, with support from Natalja Eigo and Andrew Siroka
from WHO headquarters, Fe Dy-Liacco and Ding Wang from WHO/WPRO. Chapter 7 was prepared by
Rie Fujisawa and Anamaria Verdugo (OECD Health Division), with support from Hardeep Sandhu and
Josaia Tiko from WHO/WPRO.
Valuable input was received from Mengjuan Duan, Alpha Grace Tabanao and Tracy Yuen from
WHO/WPRO, Rakesh Mani Rastogi, Ruchita Rajbhandary and Tarun Jain from WHO/SEARO, and
Frederico Guanais (OECD Health Division).
This publication benefited from the comments and suggestions of Kidong Park (Director, Data, Strategy
and Innovation, WHO/WPRO), Manoj Jhalani (Director, Health Systems Development, WHO/SEARO),
Jeong Joung-hun (Director General, Health and Social Policy Programme, OECD/Korea Policy Centre)
and Francesca Colombo (Head of OECD Health Division).
Thanks go to Lucy Hulett (OECD) for editorial assistance.
For this seventh edition of Health at a Glance: Asia/Pacific, 27 regional countries and territories were
compared: 22 in Asia (Bangladesh, Brunei Darussalam, Cambodia, China, Democratic People’s Republic
of Korea, Hong Kong (China), India, Indonesia, Japan, Korea, Lao People’s Democratic Republic, Macau
(China), Malaysia, Mongolia, Myanmar, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, Thailand and
Viet Nam) and five in the Pacific region (Australia, Fiji, New Zealand, Papua New Guinea and Solomon
Islands).
We follow OECD guidelines concerning the names of countries and territories, and those guidelines may
differ from those of the WHO.
The indicators have been selected on the basis of being relevant to monitoring health systems
performance, taking into account the availability and comparability of existing data in the Asia/Pacific
region. The publication takes advantage of the routine administrative and programme data collected by
the World Health Organization, especially the Regional Offices for the Western Pacific and South-East
Asia, as well as special country population surveys collecting demographic and health information.
The indicators are presented in the form of easy-to-read figures and explanatory narratives. Each of the
topics covered in this publication is presented over two or three pages. The first page (s) defines the
indicator and notes any methodological or contextual concerns which might affect data comparability. It
also provides brief commentary highlighting the key findings from the data analyses. On the facing page
is a set of figures. These typically show the latest levels of the indicator across countries and, where
possible, trends over time. When appropriate, an additional figure describing the relationship between two
comparable indicators variable is included.
The cut-off date for all the data reported in this publication was Friday 21 October 2022.
Averages
Countries and territories are classified into four income groups – high, upper-middle, lower-middle, and
low – based on their Gross National Income (GNI) per capita (current USD) calculated using the Atlas
method (World Bank). The classification reported in the table below and used in this publication is the one
updated on the 1 July 2021.
In text and figures, Asia Pacific-H refers to the unweighted average for high-income reporting Asia-Pacific
countries and territories, Asia Pacific-UM refers to the unweighted average for upper-middle income
reporting Asia Pacific countries and territories, and Asia Pacific-LM/L refers to the unweighted average for
lower-middle and low-income reporting countries and territories.
“OECD” refers to the unweighted average for the 38 OECD member countries. It includes Australia, Japan,
New Zealand and Korea. Data for OECD countries are generally extracted from OECD sources, unless
stated otherwise. For some indicators where data is not available for all 38 OECD countries, averages
were calculated based on information available and are denoted in figures using OECDXX, where XX
represents the number of OECD countries included in the average.
Even if from a statistical viewpoint the use of a population-weighted average is sound, the unweighted
average used in this report allows for a better representation of levels and trends observed in countries
and territories with small population numbers.
Country and territory ISO codes, GNI per capita and classification by income level
Country/territory name Country/territory short ISO code GNI per capita World Bank Classification
name (used hereafter) in international $ classification by used in this
(2020) income level report
Australia Australia AUS 52 230 High H
Bangladesh Bangladesh BGD 6 240 Lower-middle LM/L
Brunei Darussalam Brunei Darussalam BRN 67 580 High H
Cambodia Cambodia KHM 4 250 Lower-middle LM/L
People’s Republic of China China CHN 17 070 Upper-middle UM
Democratic People’s Republic of Korea DPRK PRK Low LM/L
Fiji Fiji FJI 11 420 Upper-middle UM
Hong Kong (China) Hong Kong (China) HKG 62 420 High H
India India IND 6 440 Lower-middle LM/L
Indonesia Indonesia IDN 11 750 Lower-middle LM/L
Japan Japan JPN 43 630 High H
Korea Korea KOR 45 570 High H
Lao People’s Democratic Republic Lao PDR LAO 7 750 Lower-middle LM/L
Macau (China) Macau (China) MAC 72 260 High H
Malaysia Malaysia MYS 27 360 Upper-middle UM
Mongolia Mongolia MNG 11 200 Lower-middle LM/L
Myanmar Myanmar MMR 4 960 Lower-middle LM/L
Nepal Nepal NPL 4 040 Lower-middle LM/L
New Zealand New Zealand NZL 43 890 High H
Pakistan Pakistan PAK 5 330 Lower-middle LM/L
Papua New Guinea Papua New Guinea PNG 4 240 Lower-middle LM/L
Philippines Philippines PHL 9 030 Lower-middle LM/L
Singapore Singapore SGP 86 340 High H
Solomon Islands Solomon Islands SLB 2 680 Lower-middle LM/L
Sri Lanka Sri Lanka LKA 12 850 Lower-middle LM/L
Thailand Thailand THA 17 780 Upper-middle UM
Viet Nam Viet Nam VNM 10 410 Lower-middle LM/L
Executive summary
Health at a Glance: Asia/Pacific 2022 presents key indicators on health status, determinants of health,
health care resources and utilisation, health expenditure and financing, and quality of care for 27 Asia-
Pacific countries and territories. Countries and territories in the Asia-Pacific region are diverse, and their
health issues and health systems differ. However, these indicators provide a concise overview of the
progress of countries towards achieving universal health coverage for their population.
During the COVID-19 pandemic, life expectancy has decreased by one year in lower-middle and
low-income Asia-Pacific countries from 2019 to 2021, while it decreased by 0.4 years un upper-
middle income countries and slightly increased in high-income countries during the same period.
In 2020, the average neonatal mortality rate amongst lower-middle and low-income countries in
Asia-Pacific was 15.8 deaths per 1 000 live births, almost halving the rate observed in 2000 but
still above the SDG target of 12 deaths or less per 1 000 live births.
Maternal mortality ratio averaged around 140 deaths per 100 000 live births in lower-middle and
low-income Asia-Pacific countries and territories in 2019, still two times higher than the SDG target
of less than 70 death per 100 000 live births.
Almost half of total health spending came from payments made by households
out-of-pocket in lower-middle and low-income countries
In 2019, lower-middle and low-income Asia-Pacific countries spend – after adjusting for differences
in purchasing power across countries – USD 285 per person per year on health, against USD 822
and USD 3 891 in upper-middle income and high-income Asia-Pacific countries respectively.
The share of public spending in total health spending increased – on average – in all Asia-Pacific
country income groups from 2010 to 2019, but the increase was much smaller in lower-middle and
low-income Asia-Pacific countries compared to upper-middle and high-income countries: 41.4%
compared to 62.5% and 74.1%, respectively.
On average, household out-of-pocket expenditure (that is, payments made directly by households
for health services and goods) accounted for 49% of total health expenditure in lower-middle and
low-income Asia-Pacific countries in 2019, a slight decrease in the percentage share of total health
expenditure but an increase in level from 2010.
Methodology
In order to allow for cross-country comparisons of performance, countries and territories are split
according to their income group (high income, upper-middle income, lower-middle and low income).
The central tendency measures presented, for all indicators and income groups, are medians.
In order to classify countries and territories as “better than”, “close to”, or “worse than” the central
tendency of any indicator, a measure of statistical dispersion is needed to compute the reasonable
range for values close to the central tendency value, with anything above or below classified
accordingly. The preferred measure is the Median Absolute Deviation (MAD), since it is a robust
measure that is both more efficient and less biased than a simple standard deviation when outliers are
present.
Countries and territories are classified as “better than median” if they lie above the median + 1 MAD,
“worse than median” if they lie below the median – 1 MAD, and “close to the median” if they lie within
± 1 MAD from the median. Given the nature of the indicators presented, for “under age 5 mortality rate”
and “smoking”, “alcohol consumption” and “children and adolescent overweight”, countries and
territories are classified as “better than median” if they lie below the median - 1 MAD, “worse than
median” if they lie above the median + 1 MAD, and “close to the median” if they lie within ± 1 MAD from
the median.
Health status
The five (5) indicators used to compare health status are life expectancy at birth for females (2020), life
expectancy at birth for males (2020), survival to age 65 for females (2020), survival to age 65 for males
(2020), and under age 5 mortality rate per 1 000 live births (2020).
Risk factors
The five (5) indicators used to compare risk factors are the age-standardised prevalence estimates for
daily tobacco use among persons aged 15 and above for females (2020), the age-standardised prevalence
estimates for daily tobacco use among persons aged 15 and above for males (2020), the share of
population living in rural areas with access to basic sanitation (latest year available), the share of population
living in rural areas with access to basic drinking water (latest year available) and the prevalence of
overweight among children under age 5 (latest year available).
Quality of care
The four (4) indicators used to compare quality of care are the age-standardised breast cancer mortality
rate (2020), the age-standardised cervical cancer mortality rate (2020), and vaccination coverage for three
doses of diphtheria tetanus toxoid and pertussis (DTP3) and for 1st dose of measles (MCV) among children
(2021).
Source: Breast cancer mortality, see Figure 7.9. Cervical cancer mortality, see Figure 7.12. Vaccination for DTP3, see Figure 7.10. Vaccination
for measles, see Figure 7.1.
The five (5) indicators used to compare health care resources are health expenditure per capita in
international dollars (USD PPPs) (2019), the share of out-of-pocket (OOP) spending in total current health
spending (2019), the number of doctors per 1 000 population (latest year available), the number of nurses
per 1 000 population (latest year available), and the number of hospital beds per 1 000 population (latest
year available). Given the nature of the indicators presented, where a higher or lower value may not be
indicative of better or worse performance, the arrows simply imply that the values are significantly higher
or lower than the median using the same methodology.
Source: Health spending, see Figure 6.1. Out-of-pocket spending, see Figure 6.8. Doctors per 1 000 population, see Figure 5.1. Nurses per
1 000 population, see Figure 5.2. Hospital beds per 1 000 population, see Figure 5.11.
COVID-19 has had a huge impact across the Asia-Pacific region, testing
the resilience of economies and health systems, and placing an immense
pressure on health workers operating at the front line. This chapter
analyses the direct impact of the pandemic on the health of the populations
by looking at COVID-19 cases and deaths as well as its indirect impact by
assessing the disruption to essential health services due to COVID-19. It
also looks at country responses to the pandemic based on the pandemic
situations and national capabilities and contexts. These analyses show that
COVID-19 has had an unequal impact in the region between high-, middle-
and low-income countries, in particular by amplifying inequities and
inequalities.
The health impact of COVID-19 in Asia-Pacific countries has been tremendous. More than 144 million people
tested positive for COVID-19, and more than 1 million deaths have been registered from the virus from
1 January 2020 to 18 October 2022. Comparing worldwide, the health impact might appear less significant
than in other regions, as whilst the Asia-Pacific region makes up 37% of the global population, only 14% of
cases and 4% of deaths globally were reported from the region. However, as many infected people are
asymptomatic, and due to under-reporting, these figures might not reflect the true impact of COVID-19. This
is confirmed by an increasing number of studies that suggest that the real magnitude of infections have been
much larger than those officially reported in many regions (Byambasuren, 2021[1]; Ioannidis, 2021[2]).
In Asia-Pacific countries and territories, the average cumulative number of reported cases was 28 016 per
100 000 population in high-income countries, and 3 024 per 100 000 population in lower-middle- and low-
income countries from 1 January 2020 to 18 October 2022. The average cumulative number of reported
cases in upper-middle-income countries was much lower at 689 per 100 000 population mainly due to the
low prevalence of COVID-19 in China (Figure 2.1). Among countries in the Asia-Pacific region,
Brunei Darussalam – a country with a good surveillance system – reported the highest number of
confirmed cases per 100 000 population of more than 50 000 per 100 000 population, followed by two
OECD countries in the Asia-Pacific region, namely Korea, and Australia.
Figure 2.1. COVID-19 cumulative reported cases by country, from 1 January 2020 to 18 October
2022
Cumulative COVID-19 cases per 100 000 population
60 000
50 000
40 000
30 000
20 000
10 000
Note: Data are affected by countries’ capacity to detect COVID-19 infections – which was particularly limited in many countries at the onset of
the crisis – and by the testing strategies applied. Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-
income countries; Asia Pacific LM/L, Asia-Pacific lower-middle- and low-income countries. Population data refer to May 2020.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
From 1 January 2020 to 18 October 2022, the average cumulative number of deaths per million population in
the Asia-Pacific region were 371, 48 and 247 in high-income, upper-middle-income, and lower-middle- and
low-income countries respectively, compared to 2 171 recorded deaths per million population across the
OECD. Some countries, such as Malaysia, exceeded the mark of 1 000 deaths per million population, whereas
China reported 4 deaths per million population (Figure 2.2). While most Asia-Pacific countries reported lower
death ratios compared to OECD countries, this does not necessarily imply that they were less affected, given
varying protocols, technical capacity and challenges in the attribution and reporting of the cause of death.
Figure 2.2. COVID-19 cumulative reported deaths by country, from 1 January 2020 to 18 October 2022
Cumulative COVID-19 deaths per million population
2 500
2 000
1 500
1 000
500
Note: Data are affected by countries’ protocols and challenges in the attribution and reporting of cause of death. Asia Pacific-H, Asia-Pacific
high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-Pacific lower-middle- and low-
income countries. Population data refer to May 2020.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
The number of new COVID-19 cases remained relatively low in 2020 in Asia and the Pacific. However, in
mid-2021 the number of new cases spiked in India, Indonesia and Japan. The emergence of the highly
contagious “Omicron variant” of concern contributed to the rapid increase in the number of cases in Australia
around Christmas 2021 peaking in January 2022. “Omicron” also contributed to the case numbers reaching
new heights in Japan, New Zealand and Korea in early and late March 2022, respectively. By comparison,
the increase in reported case numbers in India, Indonesia in the first quarter of 2022 was limited.
Figure 2.3. Newly reported weekly COVID-19 cases in Asia-Pacific, from 1 January 2020 to
18 October 2022
Weekly COVID-19 cases per 100 000 population
160
140
120
100
80
60
40
20
Note: Data are affected by countries’ capacity to detect COVID-19 infections – which was particularly limited in many countries at the onset of the crisis
– and by the testing strategies applied. Population data refer to May 2020. Week 2020-01: 3-9 January 2020; week 2022-41: 14-18 October 2022.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
The number of reported COVID-19 deaths in Asia-Pacific countries peaked in mid-May 2021, when about
35 000 deaths – almost 1.2 per million population – were recorded (Figure 2.4).
Figure 2.4. Weekly reported COVID-19 deaths in Asia-Pacific, from 1 January 2020 to 18 October
2022
Weekly COVID-19 deaths per million population
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Note: Data are affected by countries’ protocols and challenges in the attribution and reporting of cause of death. Population data refer to
May 2020. Week 2020-01: 3-9 January 2020; week 2022-41: 14-18 October 2022.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
Looking at the differences across countries’ income groups, lower-middle- and low-income Asia-Pacific
countries (such as Cambodia and Pakistan) showed significantly lower weekly COVID-19 cases and
deaths compared to high-income Asia-Pacific countries (such as Brunei Darussalam) and OECD countries
from 1 January 2020 to 18 October 2022 (Figure 2.5). Higher testing capacities, different testing
requirements, surveillance systems and number of health care professionals to perform testing may be
among the reasons for the observed differences.
Among the upper-middle-income Asia-Pacific countries, the low number of cases reported in China, where
a dynamic zero COVID-19 approach is still enforced (as of October 2022), has had a significant impact on
the average rate.
Figure 2.5. Weekly newly reported COVID-19 cases, Asia-Pacific countries by income level and
OECD countries, from 1 January 2020 to 18 October 2022
Note: Data are affected by countries’ capacity to detect COVID-19 infections – which was particularly limited in many countries at the onset of
the crisis – and by the testing strategies applied. Population data refer to May 2020. Week 2020-01: 3-9 January 2020; week 2022-41: 14-18
October 2022.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
The weekly death ratios in Asia-Pacific countries show a similar trend, with ratios generally lower compared
to the OECD average (Figure 2.6). Lower-middle- and low-income Asia-Pacific countries had generally
reported higher mortality ratios compared to high-income Asia-Pacific countries up until the end of 2021
when high-income Asia-Pacific countries started to report surging COVID-19 deaths.
Figure 2.6. Weekly reported COVID-19 deaths, Asia-Pacific countries by income level and
OECD countries, from 1 January 2020 to 18 October 2022
50
40
30
20
10
Note: Data are affected by countries’ protocols and challenges in the attribution and reporting of cause of death. Asia Pacific-H, Asia-Pacific
high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-Pacific lower-middle- and low-
income countries. Population data refer to May 2020. Week 2020-01: 3-9 January 2020; week 2022-41: 14-18 October 2022.
Source: WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
Differences in the evolution of new COVID-19 infections and deaths across countries reflect variations in
containment and suppression/mitigation strategies and the timing of their implementation, as well as
differences in the capacity of health systems to treat COVID-19 patients and to adapt to ongoing
challenges. While case rates peaked in 2022, deaths peaked in 2021. Vaccination campaigns, along with
better disease management and strengthened health system capacity have had a major impact in reducing
case fatality rates and in decoupling case and death rates. Moreover, the differences of the characteristics
(e.g. transmissibility, virulence and severity) in the variant of concern and its effects have also contributed
to these trends. The death rates during the Delta variant dominant period were different to the death rates
during the Omicron variant dominant period. Still, factors beyond the immediate control of policy makers –
such as geographical characteristics, population demographics, and the prevalence of certain risk factors
such as comorbidities – made some countries more susceptible than others to high rates of infection and
mortality.
Vaccines have reduced the risk of severe illness and death from COVID-19
The rollout of COVID-19 vaccines in 2021 has been a milestone in global efforts to reduce COVID-19
hospitalisation, severe disease and death, and to protect health care systems. Although the vaccination
programme started slightly later than in the United States and European countries, Asia-Pacific countries
have steadily increased their vaccination rates, reaching 80% of total Asia-Pacific population vaccinated
with a second dose at the end of 2021. However, procurement of vaccines and implementation of mass
vaccination has been challenging. In most high-income Asia-Pacific countries, vaccines are mainly sourced
through national procurement or self-produced, while most low-income Asia-Pacific countries rely on
international support by COVAX and bilateral donations to secure necessary doses.
The vaccine deployment in Asia-Pacific countries has further faced challenges such as issues affecting
delivery strategies (e.g. human resource capacity, logistical issues, and cold chain management), and
issues related to demand generation (e.g. vaccine hesitancy). Asia-Pacific countries started the booster
vaccination programme in late 2021. The launch of the third dose/booster vaccination programme was
initially delayed compared to OECD countries. However, the roll out of booster vaccination programmes in
the Asia-Pacific region was quick and by early 2022 the average number of people with a booster dose in
high- and upper-middle-income countries in the Asia-Pacific region exceeded the OECD average
(Figure 2.7). As of the end of September 2022 across the region, the percentage of the population who
received a booster dose amounts to almost 84% in high-income countries, whereas that of lower-middle-
and low-income countries is slightly below 20%. This proves that there is significant inequality and inequity
when it comes to vaccine access between high- and low-income countries in the Asia-Pacific region.
Figure 2.7. Booster vaccination progress, Asia-Pacific countries by income level and
OECD countries
80
70
60
50
40
30
20
10
0
Q3-2021 Q4-2021 Q1-2022 Q2-2022 Q3-2022
Note: Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-
Pacific lower-middle- and low-income countries.
Source: https://ourworldindata.org/coronavirus (accessed on 29 July 2022).
A high number of excess deaths was estimated for India and Indonesia
Whilst reported COVID-19 deaths are a critical measure to monitor the health impact of the pandemic,
international comparability of this indicator is limited due to differences in recording, registration and coding
practices across countries. Moreover, factors such as the low availability of diagnostic tests at the start of
the pandemic are likely to have impacted accurate attribution of the causes of death. Therefore, the
reported count of COVID-19 deaths is likely underestimated to varying degrees across countries.
An analysis of mortality from all causes – and particularly excess mortality, a measure of the total number
of deaths over and above what would have normally been expected based on death rates in previous years
at a given time of the year – provides a measure of overall mortality that is less affected by the factors
mentioned above.
In only two Asia-Pacific countries, Indonesia and India, does the number of cumulative excess deaths until
the end of 2021 exceed the OECD average, reaching 1 871 and 1 709 excess deaths per 1 million
population, respectively. Australia and New Zealand reported the highest number of negative excess
deaths (Figure 2.8).
Figure 2.8. Cumulative excess mortality by country, from 1 January 2020 to 31 December 2021
Excess deaths per million population
2 000
1 500
1 000
500
- 500
Note: Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-
Pacific lower-middle- and low-income countries.
Source: WHO, https://www.who.int/data/sets/global-excess-deaths-associated-with-COVID-19-modelled-estimates (accessed on 4 October 2022).
In 2020 and 2021, the overall number of excess deaths in the Asia-Pacific region was more than six times
higher than the reported number of cumulative COVID-19 deaths. The lowest number of excess deaths in
the Asia-Pacific region was recorded during the initial phase of the pandemic (negative 40 000 excess deaths
in April 2020), while the highest rate of excess deaths was recorded in May 2021 (135 000 excess deaths).
Lower-middle- and low-income Asia-Pacific countries show a significant gap between excess deaths and
COVID-19 reported deaths, with excess deaths approximately 8 times higher than COVID-19 deaths
(Figure 2.9). This gap is mainly driven by India and Indonesia (Figure 2.10).
Figure 2.9. Comparison of cumulative excess mortality to reported COVID-19 deaths, Asia-Pacific
countries by income level and OECD countries, from 1 January 2020 to 31 December 2021
Excess deaths COVID-19 deaths
Deaths per million population
3 000
2 500
2 000
1 500
1 000
500
- 500
OECD Asia Pacific - H Asia Pacific - UM Asia Pacific - LM/L
Note: Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-
Pacific lower-middle- and low-income countries.
Source: WHO, https://www.who.int/data/sets/global-excess-deaths-associated-with-COVID-19-modelled-estimates (accessed on 4 October
2022); WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
Figure 2.10. Comparison of cumulative excess mortality to cumulative reported COVID-19 deaths,
by country, from 1 January 2020 to 31 December 2021
Note: Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-
Pacific lower-middle- and low-income countries.
Source: WHO, https://www.who.int/data/sets/global-excess-deaths-associated-with-COVID-19-modelled-estimates (accessed on 4 October
2022); WHO, https://covid19.who.int/data/ (accessed on 21 October 2022).
When comparing monthly reported COVID-19 deaths and excess deaths, the number of excess deaths
exceeds that of COVID-19 deaths except for the early pandemic from February until May 2020
(Figure 2.11). In May 2021, the peak in excess deaths observed is mainly due to India.
Figure 2.11. Comparison of monthly COVID-19 deaths to monthly excess deaths in Asia-Pacific,
from 1 January 2020 to 31 December 2021
Life expectancy remained stable in all Asian Pacific countries between 2019 and in 2020,
while it decreased by almost one year in lower-middle- and low-income countries
between 2020 and 2021
Life expectancy at birth has remained stable – on average – for all country income groups in Asia-Pacific
between 2019 and 2020 despite the COVID-19 pandemic (Figure 2.12), while 80% of OECD member
countries reported a decrease. However, between 2020 and 2021, life expectancy has decreased by
almost one year in lower-middle- and low-income countries, while it has decreased by 0.6 years in upper-
middle-income countries and has remained stable in high-income countries. Even if interpreting these
trends in life expectancy is not entirely straightforward, evidence suggests that the life expectancy gap by
income level increased during the pandemic (Schwandt H, 2022[3]).
Figure 2.12. Comparison of life expectancy at birth in 2010, 2019, 2020, and 2021, Asia-Pacific
countries by income level
65
60
Asia Pacific - H Asia Pacific - UM Asia Pacific - LM/L
Note: Asia Pacific-H, Asia-Pacific high-income countries; Asia Pacific-UM, Asia-Pacific upper-middle-income countries; Asia Pacific LM/L, Asia-
Pacific lower-middle- and low-income countries.
Source: United Nations World Population Prospects (accessed on 29 September 2022).
While COVID-19 poses a threat to the entire population, not all population groups are similarly at risk of
adverse health outcomes of COVID-19. Vulnerable groups include those at a higher risk of susceptibility
to contracting, transmitting and recovering from the virus, such as essential workers in health and long-
term care settings with repeated exposure to the virus, and high-risk population for infections. Further,
biological based factors such as age and pre-existing health conditions increase the risk of severe health
outcomes. While age remains the largest risk factor for severe illness or death, people of all ages with
certain underlying health conditions – including obesity, cancer, hypertension, diabetes, and chronic
obstructive pulmonary disorder – face an elevated risk (ECDC, 2022[4]). Smoking and harmful alcohol use
also increases the likelihood of developing severe illness, experiencing worse health outcomes or dying
from COVID-19. The risks of adverse health outcome of COVID-19 are not equally distributed when it
comes to the vulnerable groups like refugees, migrants, indigenous peoples, ethnic minorities, people living
in slums or informal settlements or experiencing homelessness, persons with disabilities, remote or rural
locations, gender and sexual minorities, and people living in closed facilities.
The vast majority of deaths from COVID-19 have occurred in older populations. Statistics from four
OECD countries in the Asia-Pacific region show that death rates among older age groups are higher
compared to that of all ages in all countries. For example, Korea has 497 deaths per million among all
aged population, whereas the over aged 60 group showed 1953 deaths (4 times), and over 80 aged group
marked 7 479 deaths (15 times).
Comparing within countries, death rates among people over 80 were significantly higher than in the general
population (Figure 2.13). Even for Japan, where the gap in death rates between the total population and
the senior population is the lowest, the population over 60 has a 2.7 times and that aged over 80 has a
6.5 times higher death ratio compared to the whole population.
Further, there are additional factors that create inequities and influence the level of vulnerability of specific
groups and the access they have to health and social services. This was demonstrated during the
pandemic, where the risks of adverse health outcome of COVID-19 were not equally distributed. Many
social determinants of health – income, employment, housing, physical environment, gender, disability,
indigeneity, social inclusion, education, food security and working conditions – influence COVID-19
outcomes. This includes but are not limited to refugees, migrants, indigenous peoples, ethnic minorities,
people living in slums or informal settlements or experiencing homelessness, persons with disabilities,
remote or rural locations, gender and sexual minorities, and people living in closed facilities.
Figure 2.13. Reported COVID-19 deaths by population age groups (through August 2022), selected
Asia-Pacific countries
All ages People aged 60 and over People aged 80 and over
COVID-19 deaths per million population
10 000
9 000
8 000
7 000
6 000
5 000
4 000
3 000
2 000
1 000
0
Australia Japan Korea New Zealand Philippines
Note: Data for Australia include all COVID-19 deaths (both doctor and coroner certified) that occurred and were registered by 30 June 2022.
Data for Japan are from 30 April 2020 to 9 August 2022. Data for New Zealand and Korea are up to 17 August 2022. Data for the Philippines
are up to July 2021.
Source: Australia: https://www.abs.gov.au/statistics/health/causes-death/provisional-mortality-statistics/jan-apr-2022; Japan:
https://covid19.mhlw.go.jp/en/; New Zealand: https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-data-and-statistics/covid-19-case-
demographics; Korea: http://ncov.mohw.go.kr/en/bdBoardList.do?brdId=16&brdGubun=161&dataGubun=&ncvContSeq=&contSeq=&board_id=;
Philippines: Department of Health, Government of the Philippines.
The COVID-19 crisis has had a significant negative impact on population mental health. Social isolation
due to restricted mobility during the pandemic was a major driver of the increased prevalence of common
mental disorders. Such conditions and disorders, and their associated vulnerabilities may also have a
linkage with the consumption of alcohol, tobacco or illicit drugs during a pandemic. Loneliness, fear of
infection, personal suffering, grief after bereavement, and financial worries were also contributing factors
(WHO, 2022[5]; Loades et al., 2020[6]). Younger age, female gender and pre-existing health conditions were
often reported risk factors.
It is estimated that the global prevalence of anxiety and depression increased by more than 25% in the
first year of the pandemic, with young people and women particularly affected (WHO, 2022[5]). Figure 2.14
compares the prevalence of depression before and during the COVID-19 pandemic for a few countries
that have data. For example, in Australia, the prevalence of depression increased by more than
17 percentage points. Unfortunately, at a time when so many people required support, the pandemic also
disrupted the provision of mental health and social services. According to a global rapid assessment
conducted from June to August 2020, essential psychosocial support was lacking in many places, with
community-based activities and services for vulnerable groups particularly affected. On the other hand,
telemedicine was the most frequently reported strategy to overcome these service disruptions (WHO,
2020[7]).
As the full impact of the pandemic on mental health and well-being is likely to take a number of years to
fully emerge, there is a need for monitoring and measuring long-term health impacts of the pandemic. As
an example, a series of surveys in Australia has collected information from the same group of individuals
from just prior to COVID-19 and then 11 times since COVID-19 started to assess changes over time in life
satisfaction/well-being; psychological distress and mental health; loneliness; social cohesion; and financial
stress (Australian National University. Center for Social Research and Methods, 2022 [8]).
Pre-COVID 2020
Prevalence of depression or symptoms of depression
40%
35%
30%
25%
20%
15%
10%
5%
0%
Australia Japan Korea
Note: Pre-COVID refers to 2017-18 for Australia, 2014 for Japan, 2011 for Korea. The survey instruments used to measure depression differ
between countries and between time points within countries (e.g. Australia), and therefore are not directly comparable, and some surveys may
have small sample sizes or not use nationally representative samples.
Source: Korean 2011 data: Park et al. (2012[9]), “A nationwide survey on the prevalence and risk factors of late life depression in South Korea”,
https://doi.org/10.1016/j.jad.2011.12.038; other data: OECD (2021[10]), “Tackling the mental health impact of the COVID-19 crisis: An integrated,
whole-of-society response”, https://doi.org/10.1787/0ccafa0b-en.
In the early stages of the pandemic, non-COVID-19 outpatient care and hospital care was suspended or
slowed down to reduce the risk of transmission and release capacity to avoid the risk of critical care being
overwhelmed by COVID-19 patients or having the health care workforce infected and affected and not
having staff capacity. This led to major disruptions in the normal flow of patients through the health care
system. Prevention activities, primary care and chronic care for patients with non-communicable diseases
(NCDs) were paused, disrupted and transformed, to divert resources to urgent pandemic activities and to
protect staff and patients from infection, notably through the use of telemedicine and other digital tools. As
many interventions were postponed during the peak cycles of the pandemic, waiting times for elective
surgery and cancer care increased significantly in many countries.
According to the WHO’s Pulse survey on continuity of essential health services during the COVID-19
pandemic, COVID-19 continues to challenge health systems and disrupt essential health services in Asia-
Pacific. On average, one-quarter of 66 essential (tracer) services used to assess continuity of care
(e.g. elective surgeries and procedures; antenatal care; cancer treatments) were disrupted during the
pandemic (Figure 2.15). The average level of disruption reported in the Asia-Pacific is, however, half of
the level observed in the world at 45%. These findings should be interpreted with caution given the various
response rates across WHO regions. As an example, in the WHO Western Pacific region out of the
35 countries that received the 3rd round pulse survey only four countries submitted a complete survey.
Data availability was a factor here, and re-running the survey 12 months later might have improved
response rates.
Figure 2.15. Percentage and level of disruption for 66 tracer services by country, fourth quarter
2021
60%
50%
40%
30%
Average: 24%
20%
10%
0%
Outreach services and primary care services were reported to be the most disrupted across Asia-Pacific
reporting countries (Figure 2.16).
Unscheduled primary care clinic services NPL NZL SLB VNM IDN LKA
Routine schedules primary care services NPL NZL SLB VNM LKA IDN
0 1 2 3 4 5 6 7
Number of countries reporting disruption
Emergency services in Lao PDR and Nepal and primary health care service in Nepal showed an increase
of disruption over time during the pandemic (Figure 2.17).
Figure 2.17. Comparison of the disruption to service availability, first quarter 2021 and fourth
quarter 2021
5
LKA LKA
4
IDN IDN NPL NPL LKA LKA
3
NPL NPL LAO LAO BGD BGD
2
BGD BGD BGD BGD LAO LAO
1
LAO LAO LKA LKA NPL NPL
0
Q1 2021 Q4 2021 Q1 2021 Q4 2021 Q1 2021 Q4 2021
Routine PHC
Emergency services Elective surgeries
Note: Only countries reporting some or zero level of disruption in both rounds of the PULSE survey were included in this chart.
Source: WHO PULSE surveys, 2021 and 2022.
At service type level, a decrease in the level of disruption between the third quarter of 2020 and the fourth
quarter of 2021 was observed (Figure 2.18).
Figure 2.18. Comparison of the disruption to selected tracer services, second quarter 2020 and
fourth quarter 2021
8
KHM KHM BRN BRN
7
BGD IDN IDN MNG BGD LKA
6
IDN LAO BGD IDN IDN KHM
5
LAO VNM KHM MYS LAO LAO
4
NPL BGD MNG BGD NPL IDN
3
NZL NPL LKA KHM LKA BGD
2
LKA NZL LAO LAO MNG MNG
1
VNM LKA MYS LKA KHM NPL
0
Immunisation - round 1 Immunisation - round 3 Mental, neurological, Mental, neurological, Nutrition - round 1 Nutrition - round 3
substance use - round 1 substance use - round 3
Source: WHO PULSE surveys (rounds 1 and 3), 2021 and 2022.
Disruption is due to a mix of supply and demand side factors. The most commonly reported factor on the
supply side was the cancellation of elective services and the redeployment of staff to provide COVID-19
relief, unavailability of services due to closings, and interruptions in the supply of medical equipment and
health products. On the demand side, decreased care seeking decisions due to a fear of infections are the
most common cause of disruption of essential services (Table 2.1).
Type of service Indonesia Lao PDR Nepal New Zealand Sri Lanka Viet Nam
Elective Unintended Decreased
surgeries disruptions due to care-seeking
lack of health care
resources
Health post and Intentional service Decreased Decreased
home visits by delivery care-seeking care-seeking
CHWs modifications
Outreach Unintended Decreased Decreased Decreased Unintended
services disruptions due to care-seeking care-seeking care-seeking disruptions due to
lack of health care lack of health care
resources resources
Hospital inpatient Decreased Unintended Decreased Decreased
services care-seeking disruptions due to care-seeking care-seeking
lack of health care
resources
Appointment with Decreased Decreased Decreased Decreased
specialists care-seeking care-seeking care-seeking care-seeking
Routine vaccination is a backbone of individual and public health, and a prerequisite for resilient health
systems. The COVID-19 pandemic, however, has challenged the continuation of routine vaccination
programmes, and induced disruptions in infancy and childhood vaccination programmes covering children
aged 9 weeks to 6 years in Asia-Pacific countries, due to patients’ fear of infection, restrictions on
movement/travel, and limited access to health care (Harris et al., 2021[11]).
In about one-third of countries in the Asia Pacific, childhood vaccination rates decreased in 2020 (Figure 2.19).
Between March and April 2020, vaccination coverage decreased by 23% for measles and 22% for bacille
Calmette-Guérin (BCG) (GAVI, 2020[12]). In Pakistan, for example, all mass vaccination programmes were
suspended between April and June 2020 and 40 million children missed their polio vaccination during this
period (Haqqi et al., 2020[13]). In Korea, however, vaccination rate increased 1% for Hep B and BCG for infant
and measles and pneumococcus for children in 2020, compared to the rate in 2019.
Figure 2.19. DPT vaccination rate decreased in about one-third of countries in Asia Pacific in 2020
The HPV vaccination rate decreased in Australia, Fiji and Malaysia in 2020 (Figure 2.20), to then increase
to reach the 2019 levels in 2021.
90
80
70
60
50
40
30
20
10
80 72 82 88 89 90 56 49 57 96 83 85
0
Australia Brunei Darussalam Fiji Malaysia
The vaccination rate of influenza among the elderly increased between 2019 and 2020 in Australia, Japan
and New Zealand, whereas it decreased in Korea (Figure 2.21).
A study found that the major reasons for vaccination reluctancy among Asian general populations were
doubts about the safety and efficacy of the vaccine. Many people did not regard themselves to be
vulnerable to the flu and regarded vaccination as unnecessary. Looking at an individual country, a Chinese
study on parent-reported vaccination behaviours showed that children and adolescents from larger families
whose parents had lower levels of education were less likely to improve prevention behaviours (Hou et al.,
2021[14]). As socio-economic status also affects vaccination behaviours, improvements in health literacy
and promotion of vaccine safety might be a key to achieve higher flu vaccine coverage.
Figure 2.21. Influenza vaccination rate among the elderly generally increased in 2020
2019 2020 2021
% of adults aged 65 or more vaccinated
100
90 85.8
80.7
80 73
69
70 66
62.2 61.9 62
60 56.2
50
50
40
30
20
10
0
Australia Japan Korea New Zealand
During the early period of the pandemic, cancer screening was substantially disrupted (Fujisawa, 2022[15]).
Cancer screenings were halted in countries including Australia, Japan, New Zealand and Singapore. In
Japan, local governments and health care providers suspended cancer screening programmes in
accordance with the recommendation issued by the Ministry of Health, Labour and Welfare based on the
first declaration of a state of emergency on 7 April 2020. Countries also faced additional indirect challenges
in relation to cancer screening. In Australia, for instance, the drop in cancer incidence could be explained
by the need to confirm any diagnosis with pathological tests in laboratories that are already under pressure
from CVOID-19 testing (IJzerman et al, 2020[16]).
The challenges in providing and accessing cancer screening resulted in lower breast cancer screening
uptake during the initial phase of the pandemic, and the screening rate for 2020 was also lower than the
rate for 2019 (Figure 2.22). In Australia, screening for breast cancer among women aged 50-69 fell by 20%
between January and September 2020, compared to the same period in 2018, with the decline particularly
pronounced between March and May 2020, when breast screening services were paused (Australian
Institute of Health and Welfare, 2021[17]). A decline was also observed at the early stage of the pandemic
in 2020 in other countries including Japan (Toyoda et al., 2021[18]). In New Zealand, mammography
screening rates continued to decrease in 2021. Similar trends are reported for screening of cervical cancer.
A decline in cervical cancer screening was seen in Australia (Australia Government Department of Health,
2020[19]) and Japan (Japan Times, 2020[20]). The number of Cervical Screening Tests conducted was
expected to be lower in 2020 than in 2019, irrespective of the COVID-19 pandemic and subsequent
restrictions. This is largely due to the programme changing from 2-yearly Pap tests to 5-yearly Cervical
Screening Tests from December 2017, as most screening people were due for their first HPV test 2 years
after their last Pap test (during the years 2018 and 2019), with screening in 2020 mainly comprised of
people overdue for their first HPV test and those newly-screening (Australian Institute of Health and
Welfare, 2021[17]).
40
20
0
Australia Korea New Zealand
40
20
0
Korea New Zealand
Colorectal cancer screening was also suspended in several countries, including New Zealand and
Singapore during early stage of outbreak in 2020 (Chiu et al., 2021[21]; OECD, 2021[22]). In Korea, beside
breast, cervical and colorectal cancer, the uptake for gastric, liver and lung cancer screenings also declined
in 2020 compared to 2019 (Kim, 2021[23]). Another Korean study also found that metropolitan areas faced
a larger decrease in stomach, colorectal, breast and cervical cancer screening compared to rural areas.
Consequently, newly diagnosed cancer cases declined in countries with available data including Australia,
Japan, Korea, and Hong Kong (China).
Hong Kong (China)’s public laboratory faced a drastic decrease in the number of pathologic specimens
received (Vardhanabhuti and Ng, 2021[24]). As a result, the reduction in the diagnosis of malignant lesions
was observed compared to the expected number from past three years. Large declines were observed
especially for colorectal (–10.0%) and prostate (–19.7%) cancers.
A Japanese study reveals the number of newly diagnosed cancer in 2020 was 5.8% lower compared to
the previous year. Especially, May 2020 when the country was under the state of emergency showed the
most significant decrease of 22%. Gastric cancer saw the most substantial decrease of 39.1% compared
to the last four years.
Delayed cancer screening is expected to increase the future burden of cancer. An Australian study
estimated that a one-year pause in screening reduces 5-year breast cancer survival from 91.4% to 89.5%
(Feletto et al., 2020[25]). In New Zealand, cancer registrations – as recorded in a nationally-mandated
register of all new diagnoses of primary malignant cancers diagnosed – declined by 40% during its national
lockdown in 2020, compared to the previous year (Gurney et al., 2021[26]). While it took few months to go
back to its pre-COVID level, the cumulative of cancer registrations finally surpassed that of 2019 in
September 2020.
After the initial phase of the pandemic, cancer screening uptake started increasing across countries,
although to a varying degree. In Australia, for example, screening uptake between mid-July and mid-
September 2020 exceeded the corresponding period in 2018 (Cancer Australia, 2020[27]). To increase the
uptake of cancer screening, Japan ran public awareness campaigns.
Delayed and missed care for chronic conditions has been associated with worse health
outcomes
Patients with chronic health conditions have high health care needs and are at risk of complications if their
conditions are not well managed. Evidence shows how delays or missing regular care for a range of chronic
conditions, such as diabetes, exacerbates health complications and leads to severe health consequences.
In Korea, chronic respiratory disease such as COPD and asthma all saw a substantial decrease in
hospitalisations during COVID-19 (Huh et al., 2021[28]). The cumulative incidence of admissions was 58%
(COPD) and 48% (asthma) of the average rate during the four preceding years.
Early evidence shows that rates of diabetes-related complications have increased in several countries
during the pandemic due to decreased access to diabetes care and services (Khader, Jabeen and Namoju,
2020[29]; Ghosal et al., 2020[30]). For example, in Indonesia, 69.8% of patients with diabetes experienced
difficulties in managing their diabetes during the pandemic (Kshanti et al., 2021[31]). The difficulties included
attending diabetes consultation (30.1%), access to diabetes medication (12.4%), and checking blood
glucose levels (9.5%). Complications related to diabetes occurred in 24.6% of patients, with those who
had diabetes management difficulties 1.4 times more likely to have diabetes complications than those who
did not. In addition, a study on central India found that glycaemic control deviated during the lockdown
period, with a 0.51% increase in mean haemoglobin (HBA1c) for diabetes patients immediately after
lockdown, which may lead to a considerable increase in the annual incidence of complications associated
with diabetes (Khare and Jindal, 2021[32]).
In Japan, the severity of myocardial infarction also increased (Yasuda et al., 2021[33]).
Governments within the Asia-Pacific region and beyond put together substantial response packages to
combat COVID-19. The health sector was an early recipient of these additional resources. Amongst Asia
and Pacific countries with comparable data, central government budgetary commitments to health system
responses to COVID-19 between April 2020 and mid-November 2021 ranged from around 5% of GDP in
Nepal to around 0.1% in Lao PDR (Figure 2.23). However, for some countries this may not represent the
full picture of mobilisation of resources in response to COVID-19 as funds granted by international
agencies, foreign government or NGOs are not included.
Figure 2.23. Government financial commitments to health from April 2020 to November 2021
% of GDP
6
Note: Reported as a percentage of the 2020 GDP. The Asian Development Bank Policy Database displays the monetary amounts announced
or estimated by the 68 members of the Asian Development Bank, two institutions, and nine other economies (i.e. a total of 79 entries) to fight
the COVID-19 pandemic.
Source: Asian Development Bank COVID-19 Policy Database (accessed on 27 September 2022).
In addition to allocating funds for maintaining essential health services improving resilience, governments
invested in digital health and in access to medicines and supplies (Figure 2.24).
Figure 2.24. Countries reporting investments for long-term health system recovery and/or
resilience for future health pandemics in selected areas, Q4 2021
6
AUS AUS AUS AUS
5
IDN IDN IDN IDN IDN
4
LAO LAO LAO LAO LAO LAO LAO
3
NZL NZL NZL NZL NZL NZL NZL
2
LKA LKA LKA LKA LKA LKA LKA
1
BGD BGD BGD BGD BGD BGD BGD
0
Government allocated Government allocated Investment made in Invested made in Investment made to Investment made in Investement made to
funds for maintaining funds for health new facility digital health strenghten health access to medicines support infodemic
essential health system recovery infrastructure workforce and supplies management
services during the and/or health service
pandemic resilience and
preparedness
The rapid development of remote consultations has offset at least partly the reduction of
in-person encounters with GPs and specialists
Examples of regulatory and policy interventions in the Asia-Pacific region include India’s Telemedicine
Practice Guidelines 2020 and interim guidance on use of telemedicine by Indonesia permitting doctors and
dentists to provide telemedicine services through mobile apps and Information and Communication
Technologies (ICT) systems. This latter was further supported by the Indonesian Medical council issuing
a regulation regarding the Clinical Authority and Medical Practice through Telemedicine during COVID-19.
Australia expanded the range of telehealth services subsidised on a fee-for-service basis to enable GPs,
specialists and other providers to maintain care for patients and temporarily doubled the incentive fee
payable for GPs to see certain categories of patients without any upfront cost. Furthermore, there were
two additional temporary incentive payments established to provide further incentive for GPs to see
patients at risk of COVID-19 without any upfront cost. Some telehealth items that were temporarily added
have now been permanently included in the MBS schedule (Australian Government - Department of Health
and Aged Care, 2022[34]). In Australia, telemedicine was also utilised to maintain health care support for
diabetes patients, with 80.8% of patients having a telehealth consultation during the pandemic 1 (Imai et al.,
2022[35]; Olson et al., 2021[36]). Six-monthly HbA1c testing and HbA1c levels had no significant difference
between those patients who had telehealth services and those who had face-to-face consultations. In the
quarter ending September 2020, 13.3% of all Medicare Benefits Schedule services processed,
15.5 million, were telehealth consultations, indicating the importance of such services in maintaining
access to care throughout the pandemic (AIHW, 2021[37]). Remote consultations were also widely used to
provide mental health related services and between 16 March 2020 and 27 September 2020, 2.5 million
Medicare-subsidised mental health related services were delivered via telehealth nationally, which
accounts for more than a third of all mental health related services delivered in that period (AIHW, 2022[38]).
The positive impact of telehealth was particularly pronounced in antenatal care, where a 10% drop in in-
person care between January and September 2020, compared to 2019, was almost entirely offset by an
uptake of 91 000 telehealth services (AIHW, 2021[39]). Australia further implemented e-prescribing from
May 2020 onwards, allowing health care providers to send electronics prescription to individuals via SMS
or email (Australian Digital Health Agency, n.d.[40]). Moreover, pharmacists were allowed to dispense
essential medicines without a prescription from a physician in the event that it was not practicable for a
patient to receive a new prescription to allow continuity of care to a patient that had been previously
prescribed the medicine (Australian Government. Department of Health and Aged Care, 2022[41]).
While in New Zealand telehealth services were used even before the pandemic, after March 2020 some
restrictions were relaxed, which, for instance, enabled the provision of telehealth services also to patients
who had not consulted a provider in-person before (OECD, forthcoming[42]). In New Zealand, remote
technologies were further used to facilitate repeated medication prescriptions (Al-Busaidi IS, 2020[43]).
Japan and Korea also temporarily allowed the use of telehealth services to ensure access and continuity
of care during the pandemic and made the legal and policy changes required to do so (OECD,
forthcoming[42]). In Korea as in many other countries, such legislative or regulatory changes were
introduced for a limited amount of time only to respond to the unprecedented effects of the COVID-19
pandemic, even though some countries are considering a permanent integration of telehealth into their
health care systems (OECD, forthcoming[42]).
While the widespread use of telehealth during the pandemic is remarkable, there is an urgent need for
more evidence about quality and cost-effectiveness of telehealth services in improving outcomes for those
living with chronic diseases, which is still rather limited (Al-Busaidi IS, 2020[43]). At the same time, many
obstacles to care still exist, including equal access to technology and new digital tools, and appropriate
digital health literacy (Hinchman et al., 2020[44]).
Community health workers (CHWs) in the South-East Asian countries responded to the COVID-19
pandemic by expanding their routine work in different ways (Bezbaruah et al., 2021[45]). In Bangladesh,
community health volunteers (CHVs) in refugee camps performed multiple roles such as visiting the camps’
residents, providing COVID-19 information on hygiene and symptoms, and looking for suspicious cases
and advising on patient care (Rahman and Yeasmine, 2020[46]). They also provided mental health support
where necessary, while maintaining their routine health care support. India’s most crowded slum’s
COVID-19 response was achieved by relying on CHWs who knew the local area and gained trust by the
community (Singh, 2020[47]; Shaikh, 2020[48]). CHWs in slums provided necessary information on
COVID-19 and delivered essential groceries and medicine, while supporting screening with thermal
scanner and pulse oximeter.
Thailand utilised pre-existing village health volunteers (VHV) to address the nation-wide COVID-19
pandemic. VHVs were given new roles in the primary health care system, supported local epidemiological
surveillance, helped to distribute the necessary medications for patients with chronic disease, and
promoted the COVID-19 prevention scheme.
General practices in Australia and New Zealand, which experienced several disasters between 2009 and
2016, undertook a range of critical roles in providing responsive health care. These included providing
primary health care in alternative health care facilities, adapting existing health facilities for the purposes
of providing disaster health care, and maintaining care continuity for management of chronic diseases. As
such, primary health care is key for effective health emergency management both for absorbing and
recovering from a shock.
Singapore’s Public Health Preparedness Clinics, which are pre-existing community-based facilities,
provided increased access to primary care during the COVID-19 pandemic (Lim and Wong, 2020[49]).
These facilities helped to distribute PPEs, provide patients with necessary care, and thereby helped reduce
local transmission (Sim et al., 2021[50]).
Conclusions
COVID-19 has had a huge impact across the Asia-Pacific region, testing the resilience of economies and
health systems, and placing an immense pressure on health workers operating at the front line. However,
COVID-19 has had an unequal impact in the region between high-, middle- and low-income countries, in
particular by amplifying inequities and inequalities.
In terms of the overall health impact, India and Indonesia were the most affected, based on data on
COVID-19 reported deaths. In contrast, most countries situated in South-East Asia as well as Pacific
Islands countries, have been less adversely affected to date. Variation in population density, the rural-
urban composition, the degree of international visitors, as well as demographic characteristics, among
others, may well explain these observed differences in death rates. Differences in the timing, use and
intensity of public health and social measures, in particular restrictions on movement, the speed and
effectiveness in which they were implemented, and testing and contact tracing infrastructure have also
played a role (International Monetary Fund, 2020[51]).
As of September 2022, the percentage of the population who received a booster shot amounts to
almost 84% in high-income countries, whereas that of lower-income countries is slightly below 20%. This
confirms that there is significant Inequity when it comes to vaccine access between high- and low-income
countries in the Asia-Pacific region.
A WHO rapid situation assessment survey also illustrates that essential services have been severely
disrupted since the COVID-19 pandemic began. This could lead to a substantial number of additional
deaths and years of life lost, in particular in low- and middle-income countries.
While the widespread use of telehealth during the pandemic is remarkable, there is an urgent need for
more evidence about the cost-effectiveness of telehealth in improving outcomes for those living with
chronic diseases.
COVID-19 has had major effects on countries’ economies, social and health systems. It is critical to ensure
that economic pressures do not divert already limited resources away from essential health services in
low- and middle-income countries.
References
AIHW (2022), COVID-19: looking back on health in 2020, Australian Institute of Health and Welfare, [38]
Canberra, https://www.aihw.gov.au/reports-data/australias-health-performance/covid-19-and-looking-
back-on-health-in-2020 (accessed on 5 May 2022).
AIHW (2021), Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme: [37]
quarterly data, Impact on MBS service utilisation, Australian Institute of Health and Welfare, Canberra,
https://www.aihw.gov.au/reports/health-care-quality-performance/impacts-of-covid19-mbs-pbs-quarterly-
data/contents/impact-on-mbs-service-utilisation (accessed on 5 May 2022).
AIHW (2021), New report looks at uptake of telehealth in antenatal care during COVID-19 lockdowns, [39]
Australian Institute of Health and Welfare, Canberra, https://www.aihw.gov.au/news-media/media-
releases/2021-1/february/new-report-looks-at-uptake-of-telehealth-in-antena (accessed on 5 May 2022).
Al-Busaidi IS, M. (2020), “The transition to a “virtual practice” in primary care during the COVID-19 [43]
pandemic: experience from one medical centre in New Zealand”, N Z Med J, Vol. 133/1520, pp. 91-98.
Australia Government Department of Health (2020), Modelled analysis of hypothetical impacts of COVID-19 [19]
related disruptions to the National Cervical Screening Program,
https://www.health.gov.au/resources/publications/modelled-analysis-of-hypothetical-impacts-of-covid-
19-related-disruptions-to-the-national-cervical-screening-program.
Australian Government - Department of Health and Aged Care (2022), Providing health care remotely [34]
during the COVID-19 pandemic, https://www.health.gov.au/health-alerts/covid-19/coronavirus-covid-19-
advice-for-the-health-and-disability-sector/providing-health-care-remotely-during-the-covid-19-pandemic
(accessed on 28 September 2022).
Australian Government. Department of Health and Aged Care (2022), The Pharmaceutical Benefits [41]
Scheme, https://www.pbs.gov.au/pbs/home.
Australian Institute of Health and Welfare (2021), Cancer screening and COVID-19 in Australia, [17]
https://www.aihw.gov.au/reports/cancer-screening/cancer-screening-and-covid-19-in-australia-
inbrief/contents/what-was-the-impact-of-covid-19-in-australia.
Australian National University. Center for Social Research and Methods (2022), Mental health and [8]
wellbeing during the COVID-19 period in Australia,
https://csrm.cass.anu.edu.au/research/publications/mental-health-and-wellbeing-during-covid-19-period-
australia.
Bezbaruah, S. et al. (2021), “Roles of community health workers in advancing health security and resilient [45]
health systems: emerging lessons from the COVID-19 response in the South-East Asia Region”, WHO
South-East Asia Journal of Public Health, Vol. 10, https://www.who.int/publications/m/item/weekly-
epidemiological-update-8-december-2020 (accessed on 2 September 2022).
Byambasuren, O. (2021), “Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and [1]
imputed COVID-19 cases: Systematic review”, PLoS ONE, Vol. 16/4,
https://doi.org/10.1371/journal.pone.0248946.
Cancer Australia (2020), Review of the impact of COVID-19 on medical services and procedures in [27]
Australia utilising MBS data: Skin, breast and colorectal cancers, and telehealth services,
https://www.canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/review-
impact-covid-19-medical-services-and-procedures-australia-utilising-mbs-data-skin-breast-and.
Chiu, H. et al. (2021), “Mitigating the impact of COVID-19 on colorectal cancer screening: Organized [21]
service screening perspectives from the Asia-Pacific region”, Preventive Medicine, Vol. 151, p. 106622,
https://doi.org/10.1016/J.YPMED.2021.106622.
ECDC (2022), Infectious disease topics - Risk factors and risk groups, [4]
https://www.ecdc.europa.eu/en/covid-19/latest-evidence/risk-factors-risk-groups (accessed on
28 September 2022).
Feletto, E. et al. (2020), “How has COVID-19 impacted cancer screening? Adaptation of services and the [25]
future outlook in Australia”, Public Health Research & Practice, Vol. 30/4,
https://doi.org/10.17061/phrp3042026.
Fujisawa, R. (2022), “Impact of the COVID-19 pandemic on cancer care in OECD countries”, OECD Health [15]
Working Papers, No. 141, OECD Publishing, Paris, https://doi.org/10.1787/c74a5899-en.
Ghosal, S. et al. (2020), “Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic [30]
in India: A cohort analysis”, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Vol. 14/5,
pp. 949-952, https://doi.org/10.1016/J.DSX.2020.06.020.
Gurney, J. et al. (2021), “The impact of the COVID-19 pandemic on cancer diagnosis and service access in [26]
New Zealand–a country pursuing COVID-19 elimination”, The Lancet Regional Health - Western Pacific,
Vol. 10, p. 100127, https://doi.org/10.1016/j.lanwpc.2021.100127.
Haqqi, A. et al. (2020), “COVID‐19 in Pakistan: Impact on global polio eradication initiative”, Journal of [13]
Medical Virology, Vol. 93/1, pp. 141-143, https://doi.org/10.1002/jmv.26240.
Harris, R. et al. (2021), “Impact of COVID-19 on routine immunisation in South-East Asia and Western [11]
Pacific: Disruptions and solutions”, The Lancet Regional Health - Western Pacific, Vol. 10, p. 100140,
https://doi.org/10.1016/j.lanwpc.2021.100140.
Hinchman, A. et al. (2020), “Global health is local health: A multidisciplinary perspective of COVID-19”, [44]
Ochsner Journal, Vol. 20/2, pp. 123-133, https://doi.org/10.31486/TOJ.20.0059.
Hou, Z. et al. (2021), “The Influence of the COVID-19 Epidemic on Prevention and Vaccination Behaviors [14]
Among Chinese Children and Adolescents: Cross-sectional Online Survey Study”, JMIR public health
and surveillance, Vol. 7/5, https://doi.org/10.2196/26372.
Huh, K. et al. (2021), “Decrease in hospital admissions for respiratory diseases during the COVID-19 [28]
pandemic: a nationwide claims study”, Thorax, Vol. 76/9, pp. 939-941,
https://doi.org/10.1136/THORAXJNL-2020-216526.
Imai, C. et al. (2022), “Telehealth use in patients with type 2 diabetes in Australian general practice during [35]
the COVID-19 pandemic: a retrospective cohort study”, BJGP Open, p. BJGPO.2021.0200,
https://doi.org/10.3399/BJGPO.2021.0200.
International Monetary Fund (2020), Regional economic outlook update. Asia and Pacific : navigating the [51]
pandemic : a multispeed recovery in Asia.
Ioannidis, J. (2021), “Infection fatality rate of COVID-19 inferred from seroprevalence data”, Bulletin of the [2]
World Health Organization, Vol. 99, pp. 19-33, https://doi.org/10.2471/BLT.20.265892.
Japan Times (2020), Japan Cancer Society urges people to get screened after testing dived 30% in 2020, [20]
https://www.japantimes.co.jp/news/2021/04/18/national/science-health/cancer-screenings-pandemic/
(accessed on 20 August 2021).
Khader, M., T. Jabeen and R. Namoju (2020), “A cross sectional study reveals severe disruption in [29]
glycemic control in people with diabetes during and after lockdown in India”, Diabetes & Metabolic
Syndrome: Clinical Research & Reviews, Vol. 14/6, pp. 1579-1584,
https://doi.org/10.1016/J.DSX.2020.08.011.
Khare, J. and S. Jindal (2021), “Observational study on effect of lock down due to COVID 19 on HBA1c [32]
levels in patients with diabetes: Experience from Central India”, Primary Care Diabetes,
https://doi.org/10.1016/J.PCD.2020.12.003.
Kim (2021), Delayed cancer diagnosis amid pandemic could raise cancer deaths: study, [23]
https://www.koreabiomed.com/news/articleView.html?idxno=11658.
Kshanti, I. et al. (2021), “The Impact of COVID-19 Lockdown on Diabetes Complication and Diabetes [31]
Management in People With Diabetes in Indonesia:”, https://doi.org/10.1177/21501327211044888,
Vol. 12, https://doi.org/10.1177/21501327211044888.
Lim, W. and W. Wong (2020), “COVID-19: Notes From the Front Line, Singapore’s Primary Health Care [49]
Perspective”, Annals of Family Medicine, Vol. 18/3, p. 259, https://doi.org/10.1370/AFM.2539.
Loades, M. et al. (2020), “Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the [6]
Mental Health of Children and Adolescents in the Context of COVID-19”, Journal of the American
Academy of Child and Adolescent Psychiatry, Vol. 59/11, p. 1218,
https://doi.org/10.1016/J.JAAC.2020.05.009.
OECD (2021), “Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society [10]
response”, OECD Policy Responses to Coronavirus (COVID-19), OECD Publishing, Paris,
https://doi.org/10.1787/0ccafa0b-en.
OECD (forthcoming), The COVID-19 Pandemic and the Future of Telemedicine, OECD Health Policy [42]
Series, OECD Publishing, Paris.
Olson, J. et al. (2021), “COVID-19 concerns, health services utilisation and social support among Western [36]
Australians with diabetes during the pandemic”, Evaluation Journal of Australasia, Vol. 21/4, pp. 206-
225, https://doi.org/10.1177/1035719x211040857.
Park, J. et al. (2012), “A nationwide survey on the prevalence and risk factors of late life depression in [9]
South Korea”, Journal of Affective Disorders, Vol. 138/1-2, pp. 34-40,
https://doi.org/10.1016/j.jad.2011.12.038.
Rahman, A. and I. Yeasmine (2020), “Refugee health workers lead COVID-19 battle in Bangladesh camps”, [46]
UNHCR, https://www.unhcr.org/en-au/news/stories/2020/7/5f198f1f4/refugee-health-workers-lead-covid-
19-battle-bangladesh-camps.html (accessed on 2 September 2022).
Schwandt H, C. (2022), “Changes in the Relationship Between Income and Life Expectancy Before and [3]
During the COVID-19 Pandemic, California, 2015-2021”, JAMA, Vol. 328/4, pp. 360-366,
https://doi.org/10.1001/jama.2022.10952.
Shaikh, M. (2020), “Coronavirus: What is the Dharavi model being praised by WHO chief Tedros [48]
Adhanom”, India Today, https://www.indiatoday.in/india/story/what-is-the-dharavi-model-being-praised-
by-who-chief-tedros-adhanom-1699388-2020-07-11 (accessed on 2 September 2022).
Sim, S. et al. (2021), “COVID-19 in Singapore - a case series from primary care”, Singapore medical [50]
journal, Vol. 62/1, pp. 48-51, https://doi.org/10.11622/SMEDJ.2020082.
Singh, L. (2020), “BMC’s Community Health Volunteers: In the frontline of Covid fight, but poorly paid, [47]
exposed to risk”, The Indian Express, https://indianexpress.com/article/cities/mumbai/bmcs-community-
health-volunteers-in-the-frontline-of-covid-fight-but-poorly-paid-exposed-to-risk-6382159/ (accessed on
2 September 2022).
Toyoda, Y. et al. (2021), “Negative impact of the COVID-19 state of emergency on breast cancer screening [18]
participation in Japan”, Breast Cancer, https://doi.org/10.1007/s12282-021-01272-7.
Vardhanabhuti, V. and K. Ng (2021), “Differential Impact of COVID-19 on Cancer Diagnostic Services [24]
Based on Body Regions: A Public Facility-Based Study in Hong Kong”, International Journal of
Radiation Oncology, Biology, Physics, Vol. 111/2, p. 331,
https://doi.org/10.1016/J.IJROBP.2021.05.010.
WHO (2022), Mental Health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, World [5]
Health Organization, https://apps.who.int/iris/handle/10665/352189.
WHO (2020), The impact of COVID-19 on mental, neurological and substance use services: results of a [7]
rapid assessment, World Health Organization, Geneva, https://apps.who.int/iris/handle/10665/335838.
Yasuda, Y. et al. (2021), “Incidence and Demographic Trends for Acute Coronary Syndrome in a Non- [33]
Epidemic Area During the Coronavirus Disease Pandemic in Japan - A 2-Institutional Observational
Study”, Circ Rep, Vol. 3/2, https://doi.org/10.1253/circrep.CR-20-0141.
Note
1
These statistics were compiled using data supplied from practice management systems of approximately
800 general practices, so isn’t comparable with statistics derived from Medicare service data.
3 Health status
References
Dicker, D. et al. (2018), “Global, regional, and national age-sex-specific mortality and life expectancy, 1950– [2]
2017: a systematic analysis for the Global Burden of Disease Study 2017”, The Lancet, Vol. 392/10159,
pp. 1684-1735, https://doi.org/10.1016/S0140-6736(18)31891-9.
National Institute on Ageing, National Institutes of Health and WHO (2011), Global Health and Ageing. [1]
UNESCAP (2017), Inequality in Asia and the Pacific in the era of the 2030 agenda for sustainable [3]
development.
84.4
85.0
85.3
83.8
82.9
82.1
83.3
90
82.8
81.0
76.9
75.8
76.0
79.0
74.7
74.1
75.1
71.8
73.2
72.8
71.9
70.7
71.7
70.4
70.6
69.7
68.1
67.9
69.6
80
66.8
66.6
65.5
70
60
50
Source: OECD Health Statistics 2022; United Nations World Population Prospects 2022.
StatLink 2 https://stat.link/d3g4lw
Source: OECD Health Statistics 2022; United Nations World Population Prospects 2022.
StatLink 2 https://stat.link/zpt2l1
Figure 3.3. Survival to age 65 (% of cohort), Figure 3.4. Healthy life expectancy at birth by
by sex, 2020 sex, 2019
Neonatal mortality
Neonatal mortality, deaths in children within 28 days of birth, encompasses the effect of socio-economic and
environmental factors on newborns and mothers, and the capacities and responsiveness of national health
systems.
Indicators such as the education of the mother, quality of antenatal and childbirth care, preterm birth and
birthweight, Early Essential Newborn Care (EENC), and feeding practices are important determinants of
neonatal mortality (see section “Family planning” in Chapter 4). Early Essential Newborn Care (EENC) is
evidence-based, cost-effective, and comprises feasible interventions provided during childbirth and in the
postnatal period. The First Embrace is the core of EENC, defined as a life-saving practice that promotes skin-
to-skin contact immediately after birth between mother and child for no less than 90 minutes. Other EENC
interventions include: (1) ensuring the presence of a birth companion; (2) adopting a position of choice;
(3) providing adequate food and fluids; (4) using evidence-based criteria for episiotomy, and other procedures;
(5) eliminating harmful or unnecessary practices such as fundal pressure, forced pushing, and enema;
(6) administering oxytocin within one minute of birth. EENC has been introduced and scaled up across countries
and territories in Asia-Pacific (WHO, 2022[1]).
For instance, in India, three causes accounted for three out of every four neonatal deaths in 2015: prematurity and
low birthweight; neonatal infections; and birth asphyxia and birth trauma. However, even if neonatal infections and
birth asphyxia and birth trauma have steadily decreased since 2000, neonatal mortality due to prematurity and low
birthweight increased, rising from 342 000 deaths in 2000 to around 370 000 in 2015 (Fadel et al., 2017[2]).
Congenital anomalies and other conditions arising during pregnancy are also listed as primary causes of mortality
during the first four weeks of life. Undernutrition continues to be amongst the leading causes of death in both mothers
and newborns [see section “Child malnutrition (including undernutrition and overweight)” in Chapter 4]. In the Asia-
Pacific region, 72% of the deaths in the first year of life occurred during the neonatal period in 2020 (IGME, 2021[3]).
Sustainable Developing Goals set a target of reducing neonatal mortality to 12 deaths or less per 1 000 live
births by 2030. In 2020, the average amongst lower-middle- and low-income countries and territories in Asia-
Pacific was 15.8 deaths per 1 000 live births, almost halving the rate observed in 2000 but still above the SDG
target (Figure 3.5). Upper-middle-income Asia-Pacific countries almost reached the SDG target already in 2000
reporting a rate – on average – of 12.2 deaths per 1 000 live births, which then decreased to 6.2 in 2020. High-
income Asia-Pacific countries and territories reported neonatal mortality rates similar to those of the OECD, with
an average of 2.1 deaths per 1 000 live births in 2020.
In general, high-income countries and territories in Asia-Pacific experienced lower neonatal mortality rates than
lower-middle- and low-income countries and territories in the region. Singapore, Japan, Hong Kong (China),
Macau (China) and Korea reported two deaths or less per 1 000 live births in 2020, whereas neonatal mortality
rates were higher than 20 per 1 000 live births in Myanmar, Lao PDR, Papua New Guinea and India, and higher
than 40 per 1 000 live births in Pakistan.
Between 2000 and 2020, the neonatal mortality rate has fallen in almost all Asia-Pacific countries and territories
(Figure 3.5). The rate in 2020 was one-third of the rate in 2000 in DPRK and Mongolia, while in China the rate
reported in 2020 was one-sixth of the one reported in 2000. Both Brunei Darussalam and Fiji reported an
increase in neonatal mortality rates between 2000 and 2020.
Amongst the main determinants of neonatal mortality rates across countries and territories, we find income
status, geographical location, and mother education. For instance, in Pakistan, neonatal mortality is almost three
times higher in the poorest households compared to richest ones, and 50% higher when mothers have no formal
education rather than secondary or tertiary education. Geographical location is another determinant of
differences reported in neonatal mortality in the region, though relatively less impactful in comparison to
households’ income. For example, neonatal mortality rate in rural areas of Lao PDR and Pakistan was one-third
higher than the rate reported for urban areas, and a quarter higher in the case of Mongolia (Figure 3.6).
Neonatal mortality rates recede through cost-effective and appropriate interventions. These include neonatal
resuscitation training, prevention, and management of neonatal sepsis, reducing mortality from prematurity, and
prioritising the roles of breastfeeding and antenatal corticosteroids (Conroy, Morrissey and Wolman, 2014[4]).
Reductions in neonatal mortality will require not only the aforementioned strategies, but also ensuring that all
segments of the population benefit from these (Gordillo-Tobar, Quinlan-Davidson and Lantei Mills, 2017[5]).
References
Conroy, N., B. Morrissey and Y. Wolman (2014), “Reducing Neonatal Mortality in Resource-poor Settings: [4]
What works?”, Journal of Neonatal Biology, Vol. 03/03, https://doi.org/10.4172/2167-0897.1000139.
Fadel, S. et al. (2017), “Changes in cause-specific neonatal and 1–59-month child mortality in India from [2]
2000 to 2015: a nationally representative survey”, The Lancet, Vol. 390/10106, pp. 1972-1980,
https://doi.org/10.1016/S0140-6736(17)32162-1.
Gordillo-Tobar, A., M. Quinlan-Davidson and S. Lantei Mills (2017), “Maternal and Child Health: The World [5]
Bank Group’s Response to Sustainable Development Goal 3: Target 3.1 & 3.2”.
IGME, U. (2021), Levels and trends in child mortality, United Nations Inter-agency Group for Child Mortality [3]
Estimation, https://cdn.who.int/media/docs/default-source/mca-documents/rmncah/unicef-2021-child-
mortality-report.pdf.
WHO (2022), Scaling up Early Essential Newborn Care, World Health Organization Western Pacific [1]
Regional Office, https://www.who.int/westernpacific/activities/scaling-up-early-essential-newborn-care.
2000 2020
Neonatal deaths per 1 000 live births
60
50
40.4
40
30
22.3
21.7
21.5
20.3
17.5
16.9
15.8
20
12.6
13.2
11.7
11.6
10.0
8.9
7.9
7.8
6.2
6.1
4.9
10
4.6
4.0
3.5
2.6
2.6
2.4
2.1
1.5
1.4
1.1
0.8
0.8
0
Source: UN Inter-agency Group for Child Mortality Estimation (IGME) 2021; Hong Kong annual digest of statistics 2021; Macau yearbook of
Statistics, 2021.
StatLink 2 https://stat.link/ncg50i
Figure 3.6. Neonatal mortality rates by socio-economic characteristic, selected countries and
territories, nearest year
No education Secondary or tertiary education Rural Urban
Neonatal deaths per 1 000 live births Neonatal deaths per 1 000 live births
70 70
60 60
50 50
40 40
30 30
20 20
10 10
0 0
60
50
40
30
20
10
0
Bangladesh (2019) Lao PDR (2017) Mongolia (2018) Nepal (2019) Pakistan (2017-18)
Infant mortality
Infant mortality reflects the effect of social, economic, and environmental factors on infants and mothers, as well
as the effectiveness of national health systems.
Pneumonia, diarrhoea, and malaria continue to be amongst the leading causes of death in infants. Cost-effective
and simple interventions as those comprised in the EENC are key to reduce infant mortality (see section “Neonatal
mortality”). Factors such as the health of the mother, quality of antenatal and childbirth care, preterm birth and
birth weight, immediate newborn care and infant feeding practices are important determinants of infant mortality.
Infant mortality can be reduced through cost-effective and appropriate interventions -akin to the EENC
interventions for newborns. These interventions include proper infant nutrition; provision of supportive health
services such as home visits and health check-ups; immunisation and controlling the influence of environmental
factors such as air pollution; and access to safely managed water and sanitation services. Management and
treatment of neonatal infections, pneumonia, diarrhoea, and malaria is also critical (UNICEF, 2013[1]).
In 2020, amongst lower-middle- and low-income Asia-Pacific countries and territories, the infant mortality rate
was 24.1 deaths per 1 000 live births, less than half the rate observed in 2000 (Figure 3.7). Upper-middle-
income Asia-Pacific countries and territories reported a rate of 10.8 deaths per 1 000 live births, down from 19.1
in 2000. Geographically, infant mortality was lower in eastern Asian countries and territories, and higher in South
and Southeast Asia. Hong Kong (China), Japan, Singapore, Macau (China) and Korea had less than three
deaths per 1 000 live births in 2020, whereas in Pakistan more than five children per 100 live births die before
reaching their first birthday.
Infant mortality rates have fallen dramatically in the Asia-Pacific since 2000, with many countries and territories
experiencing significant declines (Figure 3.7). In China, DPRK, Mongolia and Cambodia, rates have declined in
2020 to one-third or less of the value reported in 2000, whereas rates in Fiji and Brunei Darussalam have
increased in recent years.
Across countries and territories, important inequities persist in infant mortality rates largely related to income
status and mother’s education level (Figure 3.8). In Pakistan, Lao PDR and Nepal infant mortality rates are two
to three times higher in poorest households compared to richest ones. Similarly, in Lao PDR children born to
mothers with no education had a seven-fold higher risk of dying before their first birthday compared to children
whose mothers had achieved secondary or higher education. Geographical location (urban or rural) is another
determinant of infant mortality in the region, though relatively less important in comparison to household income
or mother’s education level – except for the Lao PDR, where infant mortality in rural areas is more than twice as
high as in urban settings (Figure 3.8). Reductions in infant mortality will require not only improving quality of
care, but also ensuring that all segments of the population benefit from better access to care.
References
UNICEF (2013), Sustainable Development starts with Safe, Healthy and Well-educated Children, [1]
http://www.unicef.org/parmo/files/Post_2015_UNICEF_Key_Messages.pdf.
Figure 3.7. Infant mortality rates, 2000 and 2020 (or nearest year)
2000 2020
Infant deaths per 1 000 live births
90
75
54.2
60
35.3
45
35.2
35.0
27.0
24.3
23.6
24.1
23.0
22.0
20.9
30
19.5
16.7
16.6
13.2
10.8
11.6
9.6
7.4
7.4
15
5.5
5.9
3.9
3.7
3.3
3.1
2.6
2.2
1.8
1.8
1.5
0
Source: UN Inter-agency Group for Child Mortality Estimation (IGME) 2021; Hong Kong annual digest of statistics 2021; Macau yearbook of
Statistics, 2021.
StatLink 2 https://stat.link/sr6okn
Figure 3.8. Infant mortality rates by socio-economic characteristic, selected countries and
territories, nearest year
Lowest education Highest education Rural Urban
Infant deaths per 1 000 live births Infant deaths per 1 000 live births
100 100
90 90
80 80
70 70
60 60
50 50
40 40
30 30
20 20
10 10
0 0
References
IGME, U. (2021), Levels and trends in child mortality, United Nations Inter-agency Group for Child Mortality [3]
Estimation, https://cdn.who.int/media/docs/default-source/mca-documents/rmncah/unicef-2021-child-
mortality-report.pdf.
Perin, J. et al. (2022), “Global, regional, and national causes of under-5 mortality in 2000–19: an updated [2]
systematic analysis with implications for the Sustainable Development Goals”, The Lancet Child &
Adolescent Health, Vol. 6/2, pp. 106-115, https://doi.org/10.1016/s2352-4642(21)00311-4.
UNICEF (2013), Sustainable Development starts with Safe, Healthy and Well-educated Children, [6]
http://www.unicef.org/parmo/files/Post_2015_UNICEF_Key_Messages.pdf.
United Nations (2015), Transforming our world: the 2030 Agenda for Sustainable Development, United [1]
Nations, https://sdgs.un.org/2030agenda.
WHO (2015), Success Factors for Women’s and Children’s Health: Cambodia, World Health Organization, [5]
https://apps.who.int/iris/handle/10665/254481.
WHO/UNICEF (2006), Oral rehydration salts: production of the new ORS, [4]
https://apps.who.int/iris/handle/10665/69227.
Figure 3.9. Under age 5 mortality rates, 2000 and 2020 (or nearest year)
2000 2020
Under age 5 deaths per 1 000 live births
125
100
65.2
75
44.1
43.9
43.7
50
32.6
29.4
28.2
29.1
27.4
25.7
26.4
23.0
20.9
19.4
16.5
15.4
13.0
25
11.5
8.7
8.6
7.3
6.9
4.7
4.4
4.2
3.7
3.0
2.5
2.2
2.0
0
Source: UN Inter-agency Group for Child Mortality Estimation (IGME) 2021; Hong Kong annual digest of statistics 2021.
StatLink 2 https://stat.link/gpvsle
Figure 3.10. Under age 5 mortality rates by socio-economic and geographic factor, selected
countries and territories, nearest year
75 75
50 50
25 25
0 0
75
50
25
0
Bangladesh (2019) Lao PDR (2017) Mongolia (2018) Nepal (2019) Pakistan (2017-18)
References
Mathers, C. et al. (2005), “Counting the dead and what they died from: an assessment of the global status [2]
of cause of death data”, Bulletin of the World Health Organization, No. 83(3), World Health
Organization, https://apps.who.int/iris/handle/10665/269355.
Omran AR (2005), “The Epidemiologic Transition: A Theory of the Epidemiology of Population Change”, [1]
The Milbank Quarterly, Vol. 83/4, pp. 731-757.
Figure 3.11. All-cause mortality for all population by sex, age-standardised, per 100 000 population,
2019
Females Males
Age-standardised rates per 100 000 population
1 600 1421 1400
1 400 1264 1259 1253
1 200 1106 1090 1081 10801058
969 969 963 959 887
1 000 1090 991 846
966 777 762 738 722
800 894 686 632
600 783 794 731 749 799 749 740 732 733 511 459
703 423 414 395 382 379
604 565 569 572
400 500 443 416
200 381 317 325
225 303 247 263 205
0
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/h84b0u
Figure 3.12. All-cause mortality rates for all populations, age-standardised, 2000 and 2019
2000 2019
Age-standardised rates per 100 000 population
1 600
1 400
1 200
1245
1 000
1123
1062
1059
800
1025
989
930
893
892
877
844
840
600
810
751
734
699
697
674
630
400
573
556
499
356
404
320
318
317
312
283
200
0
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/umn02p
Figure 3.13. Proportions of age-standardised all-cause mortality rate by causes of deaths, 2019
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/kpovhy
References
Ikeda, N. et al. (2011), “What has made the population of Japan healthy?”, The Lancet, Vol. 378, pp. 1094- [2]
1105, https://doi.org/10.1016/S0140.
OECD (2015), Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care, OECD [1]
Health Policy Studies, OECD Publishing, Paris, https://doi.org/10.1787/9789264233010-en.
Ueshima, H. et al. (2008), “Cardiovascular disease and risk factors in Asia: A selected review”, Circulation, [3]
Vol. 118/25, pp. 2702-2709, https://doi.org/10.1161/CIRCULATIONAHA.108.790048.
Figure 3.14. Cardiovascular disease, estimated mortality rates, 2000 and 2019
2000 2019
Age-standardised rates per 100 000 population
850
750
650
550
450
350
250
150
282
546
537
390
363
362
345
332
331
309
301
289
276
240
239
237
236
228
224
210
203
139
122
106
95
97
73
50
68
64
-50
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/eigpuv
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/0n9wem
References
Islami, F. et al. (2017), “Cancer deaths and cases attributable to lifestyle factors and infections in China, [1]
2013”, Annals of Oncology, Vol. 28/10, pp. 2567-2574, https://doi.org/10.1093/annonc/mdx342.
OECD (2013), Cancer Care: Assuring Quality to Improve Survival, OECD Health Policy Studies, OECD [4]
Publishing, Paris, https://doi.org/10.1787/9789264181052-en.
Whiteman, D. and L. Wilson (2016), The fractions of cancer attributable to modifiable factors: A global [3]
review, Elsevier Ltd, https://doi.org/10.1016/j.canep.2016.06.013.
Wilson, L. et al. (2018), “How many cancer cases and deaths are potentially preventable? Estimates for [2]
Australia in 2013”, International Journal of Cancer, Vol. 142/4, pp. 691-701,
https://doi.org/10.1002/ijc.31088.
Figure 3.16. All cancers, estimated mortality rates, 2000 and 2019
2000 2019
Age-standardised rates per 100 000 population
250
200
194
150
156
134
134
131
100
118
117
115
115
115
114
113
108
108
105
104
101
100
96
95
95
91
90
87
87
86
84
80
50
72
0
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/ne1roi
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/f4ba5i
References
Hewlett, E. and V. Moran (2014), Making Mental Health Count: The Social and Economic Costs of [3]
Neglecting Mental Health Care, OECD Health Policy Studies, OECD Publishing, Paris,
https://doi.org/10.1787/9789264208445-en.
Peden, M. (2010), “Road safety in 10 countries”, Injury Prevention, Vol. 16/6, p. 433, [1]
https://doi.org/10.1136/ip.2010.030155.
Turecki, G. and D. Brent (2016), “Suicide and suicidal behaviour”, The Lancet, Vol. 387/10024, pp. 1227- [2]
1239, https://doi.org/10.1016/s0140-6736(15)00234-2.
WHO (2018), Global status report on road safety 2018, World Health Organization, [4]
https://apps.who.int/iris/handle/10665/277370.
2000 2019
Age-standardised rates per 100 000 population
120
100
80
89
82
75
60
67
65
65
65
62
60
60
58
57
55
53
51
40
51
50
46
42
38
37
36
40
32
32
20
30
26
24
17
0
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/lv4s93
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Note: OECD is a simple average calculated with data from WHO 2019 GHE.
Source: WHO 2019 Global Health Estimates.
StatLink 2 https://stat.link/42bkf3
Maternal mortality
Pregnancy and childbearing, whilst offering women opportunities for personal development and fulfilment, also
present inherent risks. Maternal mortality is an important indicator of a woman’s health and status. The
Sustainable Development Goals set a target of reducing the maternal mortality ratio to less than 70 deaths per
100 000 live births by 2030.
295 000 maternal deaths were estimated to have occurred worldwide in 2017, and a woman’s lifetime risk of
maternal death – the probability that a 15-year-old woman will die eventually from a maternal cause – is 0.53,
that is one woman in 190, which is approximately half the rate reported in 2000 (WHO, 2019[1]).
The leading causes of deaths are post-partum haemorrhage (PPH), infections, high blood pressure during
pregnancy, and unsafe abortion. Many of these deaths are preventable and occur in resource-poor settings
(WHO, 2019[1]). Fertility and maternal mortality have strong associations with economic development. Risk of
maternal death can be reduced through family planning, better access to high-quality antenatal, intrapartum,
and postnatal care by skilled health professionals.
Maternal mortality ratio (MMR) averaged around 140 deaths per 100 000 live births in lower-middle- and low-
income Asia-Pacific countries and territories in 2019, almost three times the upper-middle-income and more
than 15 times the high-income Asia-Pacific countries and territories average, respectively (Figure 3.20, left
panel). Estimates for 2019 show a small group of countries and territories – Singapore, Australia, Japan and
New Zealand – with very low ratios (less than 1 per 10 000 live births), whereas Solomon Islands, Nepal and
Papua New Guinea had high MMRs at 200 or more deaths per 100 000 live births. Almost 15% of the world’s
maternal deaths occurred in India and Pakistan alone.
Despite high ratios in certain countries and territories, significant reductions in maternal mortality have been
achieved in Asia-Pacific over the last 19 years (Figure 3.20, right panel). The MMR declined by 44% between
2000 and 2019 across lower-middle- and low-income Asia-Pacific countries and territories. Cambodia, Lao PDR
and Indonesia showed the largest reductions amongst countries and territories reporting ratios higher than the
low- and lower-middle-income countries and territories average in 2019. According to a study (WHO, 2015[2]),
Cambodia’s success is related to reduced fertility through wider use of contraceptives and increased coverage
of antenatal care and skilled birth attendance – achieved through increasing the number of midwives and
facilities providing Emergency Obstetric and Newborn Care. The national scale-up of the Early Essential
Newborn Care (EENC) programme – comprising simple and cost-effective interventions that benefit mothers
and newborns – is a key achievement of Cambodian Government with support from WHO.
Across Asia-Pacific countries and territories, maternal mortality is inversely related to the coverage of skilled
birth attendance (Figure 3.21). Papua New Guinea and Bangladesh reported that less than 60% of live births
are attended by skilled health professionals (see indicator “Pregnancy and birth” in Chapter 5) and present
relatively high MMRs -above 160 deaths per 100 000 live births-.
Higher coverage of antenatal care1 is associated with lower maternal mortality, indicating the effectiveness of
antenatal care across countries (Figure 3.22). Addressing disparities in the unmet need of family planning and
providing essential reproductive health services to underserved populations may also substantially reduce
maternal deaths in the region (UNESCAP, 2017[3]).
To improve quality of care, maternal death surveillance and response (MDSR) has been implemented in
countries and territories. MDSR is a continuous cycle of identification, notification and review of maternal deaths
followed by actions to prevent future death. Global survey of national MDSR system instigated in 2015 provides
baseline data on status of implementation. The implementation status of countries and territories in WPRO
(Cambodia, China, Fiji, Lao PDR, Malaysia, Mongolia and Papua New Guinea) can be found at:
http://www.who.int/maternal_child_adolescent/epidemiology/maternal-death-surveillance/en/.
References
UNESCAP (2017), Inequality in Asia and the Pacific in the era of the 2030 agenda for sustainable [3]
development.
WHO (2019), Trends in maternal mortality 2000 to 2017, World Health Organization, [1]
https://apps.who.int/iris/handle/10665/327595.
WHO (2015), Success Factors for Women’s and Children’s Health: Cambodia, World Health Organization, [2]
https://apps.who.int/iris/handle/10665/254481.
Note
1
Evidence is based on at least four times, but latest WHO Recommendations are at least eight antenatal visits,
comprising pregnancy monitoring, managing problems such as anaemia, counselling and advice on preventive
care, diet, and delivery by or under the supervision of skilled health personnel.
Figure 3.20. Estimated maternal mortality ratio, 2019 and percentage change since 2000
Estimated maternal mortality ratio Percentage change 2000-2019
Note: OECD average is based on data from OECD Health Statistics 2022.
Source: OECD Health Statistics 2022; Bill and Melinda Gates Foundation.
StatLink 2 https://stat.link/nskejc
Figure 3.21. Skilled birth attendant coverage Figure 3.22. Antenatal care coverage and
and maternal mortality ratio, latest year maternal mortality ratio, latest year available
available
Skilled birth attendant coverage (%) Antenatal care coverage, at least four visits (%)
100
Asia-H KOR BRN
SGP LKA FJI SGP FJI PRK
OECD VNM 90 LKA
100 MNG AUS THA PHL
PRK IND IDN MNG IDN
CHN MYS
BRN 80
THA KHM VNM KHM
SLB 70
PHL CHN NPL
R² = 0.5586 SLB
60 LAO
80 MMR
Asia-LM/L PAK
Asia-UM NPL IND
50
PAK PNG
40
LAO MMR BGD
BGD
60 30
PNG
20 R² = 0.5029
10
40
0 50 100 150 200 250 300 0
Maternal mortality ratio 0 50 100 150 200 250 300
Maternal mortality ratio
Source: OECD Health Statistics 2022; WHO (2021); WHO Sources: WHO GHO 2021.
GHO 2021. StatLink 2 https://stat.link/pq3k6e
StatLink 2 https://stat.link/x3ukr0
Tuberculosis
Tuberculosis (TB) is one of the leading causes of death from an infectious disease in Asia-Pacific. In 2020, there
were 5.8 million incident (new and relapsed) TB cases worldwide – a reduction from 7.1 million reported cases
in 2019 due to the COVID-19 pandemic indirect impact-, an estimated 1.3 million deaths amongst HIV-negative
people globally (WHO, 2021[1]). TB cases and deaths occur disproportionately amongst men, but the burden of
disease amongst women is also high as it remains amongst the top three killers for them in the world. Most
cases of TB are curable if diagnosed early and the appropriate treatment is provided, therefore curtailing onward
transmission of infection.
TB was declared a global health emergency by the WHO in 1993, and the WHO-co-ordinated Stop TB
Partnership set targets of halving TB prevalence and deaths by 2015 compared with a baseline of 1990. The
WHO’s End TB Strategy (post-2015) which followed the Stop TB Strategy aims at ending the global TB epidemic
by 2035, in line with the Sustainable Development Goals (Sharma, 2017[2]). In 2018, the UN General Assembly
High-Level Meeting on the fight against TB endorsed a political declaration to emphasise an importance of
accelerating progress towards End TB targets (UNGA, 2018[3]).
In Asia-Pacific, TB mortality rates were high in Nepal and Papua New Guinea with over 50 deaths of people
without HIV per 100 000 population (Figure 3.23, left panel).
South-East Asia accounted for 43% of the estimated TB cases globally in 2020, more than any other WHO
region. India (26.0% of TB cases globally), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan
(5.8%), and Bangladesh (3.6%) were amongst the most affected countries and territories in 2020 – keeping in
mind that these countries and territories also had important reductions in the reporting of cases due to the
COVID-19 pandemic – (WHO, 2021[1]). The case notification rate is particularly high in DPRK and Papua New
Guinea, at more than 300 cases per 100 000 population. An incidence rate higher than 500 cases per
100 000 population was estimated for the Philippines and DPRK, while for Australia and New Zealand less than
10 incident cases per 100 000 population were estimated (Figure 3.23, right panel).
High-quality TB services have expanded, and many cases are treated, reaching the treatment success rate for
new TB cases of more than 85% in many Asia-Pacific countries and territories in 2019 (Figure 3.24).
Nevertheless, Fiji reports a low treatment success rate at 30%. In countries and territories where TB
predominantly affects older people -such as Japan and Hong Kong (China)-, treatment success rate was lower
than 75%.
The Asia-Pacific region is rising to the challenges presented by TB. In a large part of the countries and territories,
case notification rates have declined from 2015 to 2020 (Figure 3.25). However, countries and territories like
Lao PDR, Thailand, Fiji, Indonesia, Bangladesh, Singapore, New Zealand, Australia and Brunei Darussalam are
showing upward trends, with the latter four belonging to the high-income economies group and experiencing low
base case notification rates. The region still faces important challenges in TB control, including providing
services to those in greatest need, especially the poor and vulnerable. HIV-TB co-infection, the emergence of
drug-resistant strains, a sizeable proportion of TB-affected population facing catastrophic costs due to TB,
funding gaps and the need for greater technical expertise all remain threats to progress (WHO, 2016[4]; WHO,
2019[5]). Concerning drug-resistant TB (MDR/RR-TB), the burden is high in China with 7.1% of new cases are
estimated to have MDR/RR-TB. This proportion is also high at 5.1% in Myanmar and Viet Nam, at above 4%.
Treatment of MDR/RR-TB can take up to two years and is far more costly than drug susceptible strains.
References
Sharma, D. (2017), “New plan to end tuberculosis in south and southeast Asia”, The Lancet, [2]
Vol. 389/10075, p. 1183, https://doi.org/10.1016/S0140-6736(17)30817-6.
UNGA (2018), UN General Assembly High-Level Meeting on the fight against tuberculosis, [3]
https://www.who.int/news-room/events/un-general-assembly-high-level-meeting-on-ending-tb.
WHO (2021), Global Tuberculosis Report 2021, World Health Organization, [1]
https://apps.who.int/iris/handle/10665/346387.
WHO (2016), Ending TB in the South-East Asia Region : regional strategic plan 2016-2020, WHO Regional [4]
Office for South-East Asia, https://apps.who.int/iris/handle/10665/250292.
29 Philippines 234
DPRK 348
52 Papua New Guinea 315
10 Mongolia 118
38 Myanmar 190
36 Indonesia 140
27 Asia Pacific-LM/L 153
22 Cambodia 174
21 Pakistan 124
56 Nepal 94
27 Bangladesh 140
37 India 118
11 Viet Nam 103
17 Thailand 123
25 Lao PDR 110
6 Malaysia 71
8 Asia Pacific-UM 71
5 Brunei Darussalam 72
7 Fiji 48
8 Solomon Islands 47
4 Sri Lanka 33
5 Macau (China) 56
2 China 43
2 Hong Kong (China) 49
4 Korea 46
1 Singapore 40
3 Asia Pacific-H 36
3 Japan 10
1 OECD 8
0 New Zealand 7
0 Australia 6
60 50 40 30 20 10 0 0 250 500 750 1000
Per 100 000 population Per 100 000 population
H represents lower and upper bounds.
Source: Global Tuberculosis Report 2021.
StatLink 2 https://stat.link/8u4k9o
Figure 3.24. Tuberculosis treatment success Figure 3.25. Change in tuberculosis case
for new and relapse TB cases, 2019 notification rate, 2015-20
Cambodia Lao PDR
Solomon Islands Brunei Darussalam
Bangladesh Thailand
China Australia
Pakistan Fiji
Viet Nam Indonesia
Lao PDR Asia Pacific-UM
Nepal Bangladesh
Myanmar New Zealand
Mongolia Singapore
Asia Pacific-LM/L Papua New Guinea
Philippines Viet Nam
Australia India
Thailand Macau (China)
Sri Lanka Asia Pacific-H
Macau (China) Malaysia
DPRK Asia Pacific-LM/L
India Philippines
New Zealand Hong Kong (China)
Indonesia DPRK
Korea Cambodia
Malaysia Pakistan
Singapore Mongolia
Asia Pacific-H Nepal
Brunei Darussalam China
Hong Kong (China) Sri Lanka
Asia Pacific-UM Myanmar
Papua New Guinea Japan
OECD Solomon Islands
Japan OECD
Fiji Korea
0 25 50 75 100 -50 -25 0 25 50 75
Treatment success (%) Change (%)
Source: Global Tuberculosis Report 2021. Source: Global Tuberculosis Report 2021.
StatLink 2 https://stat.link/pi4d0t StatLink 2 https://stat.link/8x20sr
HIV/AIDS
Although the first cases of AIDS in Asia were reported mid-1980s, the more extensive spread of HIV began late
compared with the rest of the world, occurring in Cambodia, India, Myanmar and Thailand in the early 1990s
(Ruxrungtham, Brown and Phanuphak, 2004[1]; UNAIDS, 2013[2]). Asia is second only to sub-Saharan Africa as
the region with the greatest number of people with HIV. The UN set an SDG target to end the epidemic of AIDS
as a public threat by 2030.
In Asia-Pacific, the prevalence of HIV infection varied importantly, ranging from less than 0.1% of adults aged 15
to 49 in Bangladesh, Mongolia, New Zealand and Sri Lanka to 1% of adults aged 15 to 49 in Thailand in 2020
(Figure 3.26, left panel). Although HIV prevalence is low, the absolute number of people living with HIV was high
at more than 2.2 million in reporting countries and territories in 2021, because of Asia-Pacific’s large population
(Figure 3.26, right panel).
Expanded access to antiretroviral therapy (ART) has increased the survival rates of people living with HIV, but
about half of the people eligible for HIV treatment do not receive it worldwide (UNAIDS, 2018[3]). The estimated
ART coverage amongst persons living with HIV in 2021 was less than half in Pakistan, Indonesia, Bangladesh,
Mongolia, the Philippines and Fiji, whereas more than three-quarters had access to ART in Thailand, Cambodia
and New Zealand (Figure 3.27).
Over past years, many countries in Asia-Pacific responded to HIV/AIDS successfully and incidence rates have
declined. Bangladesh, Singapore and Sri Lanka had less than 0.01 new case of HIV infection per
1 000 uninfected population in 2021. However, almost 0.4 new cases of HIV infections per 1 000 uninfected
population were reported in Papua New Guinea in 2021 (Figure 3.28). Moreover, the Philippines more than
tripled the new cases of HIV infection between 2000 and 2018 (UNAIDS, 2019[4]).
Advances in HIV prevention and treatment could end AIDS as a public health threat in the region. Recent
evidence has emerged showing that antiretroviral drugs not only improve the health and prolong the lives of
people living with HIV, but also prevents HIV transmission. The rapid scale up antiretroviral therapy in
recent years in Asia and the Pacific provides unprecedented opportunity to successfully implement antiretroviral-
based interventions for prevention. The benefits of ART can be fully realised only if people living with HIV are
diagnosed and successfully linked to care. This will require targeted efforts and removing barriers especially
amongst key affected populations, as most of Asia’s epidemics occur amongst sex workers and their clients,
men who have sex with men, transgender persons, and injection drug users.
References
Ruxrungtham, K., T. Brown and P. Phanuphak (2004), “HIV/AIDS in Asia”, The Lancet, Vol. 364/9428, [1]
pp. 69-82, https://doi.org/10.1016/S0140-6736(04)16593-8.
UNAIDS (2019), Communities at the centre. Global AIDS update 2019. [4]
Figure 3.27. Estimated antiretroviral therapy Figure 3.28. New HIV infections per 1 000
coverage amongst people living with HIV, uninfected population, 2021
2021
Malaria
Malaria is a tropical disease caused by a parasite transmitted by the bites of infected female Anopheles
mosquitoes. After a period spent in the liver, malaria parasites multiply within red blood cells, causing symptoms
such as fever, headache, and vomiting. Malaria is preventable and curable and recently WHO recommended a
ground-breaking malaria vaccine for children at risk (WHO, 2021[1]). Still, if left untreated, malaria can become
life-threatening by disrupting the blood supply to vital organs.
As part of the SDG targets, the UN set a goal to end the epidemic of malaria by 2030. In 2021, WHO certified
China malaria free, a significant accomplishment for China and a major milestone for malaria elimination in the
Western Pacific region. Malaysia reported zero malaria cases and is part of the WHO E-2025 Initiative to
eliminate malaria by 2025, together with Korea and Vanuatu. Meanwhile, DPRK and Thailand were selected to
participate in the E-2025 initiative towards the elimination of malaria by 2025 (WHO, 2021[2]).
About 2.31 billion people are at high risk in Asia-Pacific. Malaria-endemic countries and territories in the region
are Papua New Guinea, Solomon Islands, Pakistan, India, Nepal, the Philippines, Indonesia, Myanmar, Lao
PDR, Cambodia, Thailand, DPRK, China, Viet Nam, Bangladesh, Korea and Malaysia. Malaria transmission is
intense in some areas of Papua New Guinea and the Solomon Islands; it is also intense in focal areas in the
Greater Mekong Sub-region, including forested areas of Cambodia, Lao PDR and Viet Nam, where malaria
disproportionately affects ethnic minorities and migrant workers. Malaria is also restricted in its distribution in
Malaysia and the Philippines. Mobile and indigenous populations as well as infants, young children and pregnant
women are especially vulnerable.
In 2020, South-East Asia accounted for 2% (5 million) of the estimated 241 million malaria cases globally.
Presumed and confirmed cases were concentrated in Papua New Guinea, Myanmar and Pakistan (Figure 3.29,
left panel). Death were estimated to be 9 000 in 2020, with the highest mortality rates in Papua New Guinea and
the Solomon Islands (Figure 3.29, right panel) (WHO, 2021[2]).
For a balanced understanding, changes in the number of malaria cases should be viewed in parallel with
changes in malaria incidence. The number of estimated cases per 1 000 population at risk showed a decline in
all reporting Asia-Pacific countries and territories from 2010 to 2020, except for Papua New Guinea
(Figure 3.30). After nearly four years of maintaining zero indigenous cases, and after intensive external
evaluations including field assessments, Sri Lanka was certified by WHO as malaria-free in September 2016.
The key interventions quoted for the successful reduction of malaria burden in Myanmar were placement of
village health volunteers strategically at rural, remote, hard to reach and conflict areas, good coverage of
insecticide-treated bed nets amongst at-risk population and improved access to artemisinin-based combination
treatment (Mu et al., 2016[3]; Linn et al., 2018[4]).
The number of malaria cases not treated increased to around three out of ten in Papua New Guinea and the
Philippines, whereas it decreased significantly to less than one in six in Nepal and Bangladesh from 2000 to
2020 (Figure 3.31). During the same period, the number of malaria cases not treated doubled to one in five in
Myanmar, while they decreased by two-thirds in Cambodia and went down to almost zero in Viet Nam.
References
Linn, N. et al. (2018), “Are village health volunteers as good as basic health staffs in providing malaria [4]
care? A country wide analysis from Myanmar, 2015”, Malaria Journal, Vol. 17/1,
https://doi.org/10.1186/s12936-018-2384-4.
Mu, T. et al. (2016), “Malaria incidence in Myanmar 2005-2014: Steady but fragile progress towards [3]
elimination”, Malaria Journal, Vol. 15/1, https://doi.org/10.1186/s12936-016-1567-0.
WHO (2021), WHO recommends groundbreaking malaria vaccine for children at risk, [1]
https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-
children-at-risk.
Figure 3.29. Confirmed malaria cases and estimated mortality rates, 2020
Confirmed cases Estimated mortality rate
Papua New Guinea
0.75 0.60 Myanmar 33.11
0.24
0.37 Pakistan 0.21
0.25 Indonesia 0.53
0.19 India 0.57
0.08 Solomon Islands
18.24
0.02 Cambodia 0.36
0.01 Bangladesh 0.09
0.01 Philippines 0.15
0.00 China 0.00
0.00 DPRK 0.00
0.00 Korea 0.00
0.00 Lao PDR 0.18
0.00 Malaysia 0.00
0.00 Nepal 0.00
0.00 Sri Lanka 0.00
0.00 Thailand 0.02
0.00 Viet Nam 0.00
0.8 0.6 0.4 0.2 0 0 20 40 60 80
Million cases Per 100 000 population at risk
Figure 3.30. Changes in malaria incidence Figure 3.31. Change in the proportion of
rate, 2010-20 malaria cases not treated, 2000-20
Diabetes
Diabetes is a chronic metabolic disease, characterised by high levels of glucose in the blood. It occurs either
because the pancreas stops producing the hormone insulin (type 1 diabetes, insulin-dependent diabetes,
genetic predisposition), which regulates blood sugar, or through a reduced ability to produce insulin (type 2
diabetes, non-insulin dependent, lifestyle related), or through reduced ability to respond to insulin (i.e. insulin
resistance). People with diabetes are at a greater risk of developing cardiovascular diseases such as heart
attack and stroke. They also have elevated risks for vision loss, foot and leg amputation due to damage to nerves
and blood vessels, and renal failure requiring dialysis or transplantation.
Diabetes is one of the most common non-communicable diseases globally, affecting 422 million people in 2014,
a prevalence of 9% and 7.9% amongst the male and female adult population (18 years or older) respectively
(NCD Risk Factor Collaboration, 2016[1]). In Asia-Pacific, about 227 million people live with type 2 diabetes and
about half of them are undiagnosed and unaware of developing long-term complications. In 2012, diabetes
caused 1.5 million deaths worldwide and an additional 2.2 million deaths were related to higher-than-optimal
blood glucose (WHO, 2016[2]).
Type 2 diabetes comprises 90% of people with diabetes around the world, and until recently, this type of diabetes
was seen only in adults, but it is now also occurring in children. For many people, the onset of type 2 diabetes
can be prevented or delayed through regular physical exercise and maintaining a healthy weight (see indicators
on “Child malnutrition (including undernutrition and overweight)” in Chapter 4) and a healthy diet. The cause of
type 1 diabetes is not fully understood yet – but we know there is a genetic predisposition and environmental
factors play a role as well.
Amongst the 27 Asia-Pacific countries and territories in this report, the prevalence of diabetes for women ranged
from 5% in Australia to 18.9% in Fiji of the adult population (Figure 3.32, right panel), while the prevalence for
males ranged from 5.5% in Viet Nam to 15.9% in Fiji (Figure 3.32, left panel). In all countries and territories in
this report (except Singapore), the prevalence of diabetes amongst males increased from 2000-14, whereas the
prevalence of diabetes amongst women increases in all countries and territories but Japan, Korea,
Brunei Darussalam, Hong Kong China and Singapore.
Amongst lower-middle- and low-income Asia-Pacific countries and territories, deaths attributable to high blood
glucose increased by 14% between 2000 and 2019 (Figure 3.33). More than 260 deaths per 100 000 population
were caused by high blood glucose in adults in Fiji in 2019. This mortality rate increased by 58% in Nepal
between 2000 and 2019 and increased by more than 40% in Pakistan and Sri Lanka.
References
NCD Risk Factor Collaboration (2016), “Worldwide trends in diabetes since 1980: a pooled analysis of 751 [1]
population-based studies with 4·4 million participants”, The Lancet, Vol. 387/10027, pp. 1513-1530,
https://doi.org/10.1016/s0140-6736(16)00618-8.
WHO (2016), Global report on diabetes, World Health Organization, [2]
https://apps.who.int/iris/handle/10665/204871.
Figure 3.33. Deaths attributable to high blood glucose for adults, estimated mortality rates, 2000
and 2019
2000 2019
Age-standardised rates per 100 000 population
300
261
250
200
150 137
107
100 76 75
59 54 51 51 47 40 39
50 36 34 31 27 20 20 19 15 15 13 13 9 9 8 6 2 2
0
Ageing
Population ageing is characterised by a rise in the share of the older people resulting from longer life expectancy
(see indicator “Life expectancy at birth and survival rate to age 65” in Chapter 3) and declining fertility rates. This
has been mainly due to better access to reproductive health care, primarily a wider use of contraceptives (see
indicator “Family planning” in Chapter 4). Population ageing reflects the success of health and development
policies over the last few decades.
The share of the population aged 65 years and over is expected to double in lower-middle- and low-income
Asia-Pacific countries and territories in the next decades to reach 13.4% in 2050. This is still lower than the high-
income and upper-middle-income countries and territories average in 2050 of 31.1% and 22.3%, respectively
(Figure 3.34). The share of older people will be particularly large in Korea and Hong Kong (China) where around
40% of the population will be aged 65 and over in 2050.
Globally, the speed of ageing in the region will be unprecedented. In 2050, seven Asia-Pacific countries and
territories will be qualified as “ageing society” (as compared to 14 countries and territories in 2021), eight as
“aged society” (four countries and territories in 2021) and 11 as “super-aged society” (only one country in 2020,
that is Japan). Only Papua New Guinea is expected to show a share of population over age 65 lower that 7%,
while 14 countries and territories fulfilled this criterion in 2020. The speed of ageing is particularly fast in Papua
New Guinea and Mongolia, where the share of the population over 65 is expected to increase by more than five
and four times, respectively, between 2021 and 2050. Many low- and middle-income countries and territories
are faced with much shorter timeframes to prepare for the challenges posed by the ageing of their populations.
The growth in the share of the population aged 80 years and over will be even more dramatic (Figure 3.34). On
average across lower-middle- and low-income Asia-Pacific countries and territories, the share of the population
aged 80 years and over is expected to almost triple between 2021 and 2050, to reach 2.9% of the population.
This proportion is expected to triple and quadruple in high-income and upper-middle-income countries and
territories to reach 12.1% and 7.2% during the same period, respectively. The proportion of the population
aged 80 years and over is expected to grow by six times in Singapore and Brunei Darussalam over the next
decades.
The pressure of population ageing will depend on the health status of people as they become older, highlighting
that the health and well-being of older people are strongly related to circumstances across their life course. As
the number of older people increases, there is likely to be a greater demand for health care that meets the need
of older people in the Asia-Pacific region in coming decades. All countries and territories in the region will
urgently need to address drastic changes in demographic structures and subsequent changes in health care
needs, especially the shifting disease burden to NDCs. Health promotion and disease prevention activities will
increasingly need to address cognitive and functional decline, including frailty and falls. The health and well-
being of older adults are determined by a complex interplay of factors that accumulate across a person’s lifetime
including political, social, economic, and environmental conditions that are largely outside the health sector.
Therefore, health systems will need to be reoriented to become more responsive to older people’s changing
needs, including by investing in integrated and person-centred service delivery, supported by health financing
arrangements and a health workforce with the right skills and ways of working, and integrated health and non-
health services (e.g. welfare, social, education). The development of long-term care systems as seen in
OECD countries may also be worth noting. Increasingly, there is a need to foster innovative home- and
community-based long-term care pathways tailored to older people’s specific and diverse needs.
Over the next few decades, the increase in the population aged 65 years or more will outpace the increase in
the economically active population aged 15-64 across countries and territories in Asia-Pacific (Figure 3.35). In
2050, the ratio of people aged 15-64 to people aged over 65 years will be two-fifths of the 2021 value in upper-
middle-income Asia-Pacific countries and territories (2.6 in 2050 vs 6.5 in 2021), whereas it will be slightly less
than half the 2021 value in high (3.6 vs 7.9) and lower-middle- and low-income (5.1 vs 10.6) Asia-Pacific
countries and territories. In Macau (China), Japan, India, Singapore, Thailand and China, there will be two or
less persons aged 15-64 for each person aged over 65 years in 2050. This underscores the importance of the
society reform to encourage social participation of older people. Older adults contribute to society in a variety of
ways including through paid and unpaid work, caregiver for family members, passing down knowledge and
traditions to the younger generations.
These dramatic demographic changes will affect the financing of not only health systems but also social
protection systems, and the economy. Moreover, older age often exacerbates pre-existing inequities based on
income, education, gender, and urban/rural residence, highlighting the importance of equity-focused policy
making in future (OECD, 2017[1]). Population ageing does not only call for equity-focused, gender-responsive
and human rights-based action within the health sector but also require collaboration across sectors to address
the underlying determinants of health of older people, including housing, transport, and the built environment.
References
United Nations (2022), World Population Prospects 2022: Methodology of the United Nations population [2]
estimates and projections, United Nations,
https://population.un.org/wpp/Publications/Files/WPP2022_Methodology.pdf.
Figure 3.34. Share of the population aged over 65 and 80 years, 2021 and 2050
2021 2050
65+. 80+ 65+ 80+
Figure 3.35. Ratio of people aged 15-64 to people aged over 65 years, 2021 and 2050
2021 2050
Ratio
25 20.1
20
16.5
14.8
14.3
13.9
12.4
15
12.0
11.8
11.6
11.4
10.7
10.6
10.3
10.0
10.3
9.9
9.7
9.6
9.1
10
7.9
7.8
6.8
6.6
6.5
6.5
6.1
5.9
5.9
6.1
5.3
5.2
5.1
5.1
4.9
4.8
4.8
4.5
4.4
4.3
4.3
4.1
3.9
3.8
3.7
3.6
3.5
3.1
5
2.9
3.1
2.8
2.6
2.6
2.5
2.2
2.1
2.0
1.6
1.9
1.8
1.4
1.3
1.3
4 Determinants of health
Family planning
The UN Sustainable Development Goals set a target of ensuring universal access to reproductive health care
services by 2030, including for family planning, information and education, and the integration of reproductive
health into national strategies and programmes. Providing family planning services is one of the most cost-
effective public health interventions, contributing to significant reductions in maternal mortality and morbidity as
well as overall socio-economic development (UNFPA, 2019[1]).
Reproductive health requires having access to effective methods of contraception and appropriate health care
through pregnancy and childbirth, to allow women and their partners to make decisions on fertility and provide
parents with the best chance of having a healthy baby. Women who have access to contraception can protect
themselves from unwanted pregnancy. Spacing births can also have positive benefits on both the reproductive
health of the mother and the overall health and well-being of the child.
Modern contraceptive methods are more effective than traditional ones (WHO/Johns Hopkins Bloomberg School
of Public Health, 2018[2]). The prevalence of modern methods use varies across countries and territories in Asia-
Pacific. It was high on average across high-income and upper-middle-income countries and territories (59.2%
and 62.0%, respectively). In a few of these countries and territories including China (80.5%), New Zealand
(74.7%), Thailand (71.3%), and DPRK (68.8%), at least two-thirds of married or in-union women of reproductive
age reported using modern contraceptive methods (Figure 4.1).The average prevalence was low in lower-
middle- and low-income countries and territories (47%). In the Solomon Islands, Pakistan, and
Papua New Guinea, less than one out of three married or in-union women reported using any modern method.
Based on population sizes, fertility rates, social welfare policies and regulations and service availability,
differences in demand for family planning satisfied with modern methods exist in all reporting Asia-Pacific
countries. In Nepal, demand satisfied is 34 percentage points higher amongst women with lowest education
than amongst women with highest education, with a similar pattern observed in other reporting countries.
(Figure 4.2). In Mongolia, demand satisfied is 13 percentage points higher amongst women living in rural areas
than amongst those living in urban areas (72% versus 59%), while the proportion of women living in urban areas
reporting demand for family planning satisfied is slightly higher than the proportion of women living in rural areas
in Bangladesh (79% versus 77%), Pakistan (59% versus 56%) and Viet Nam (74% versus 71%). Based on
income levels, the demand satisfied is 15 percentage points higher amongst women from households in the
lowest income quintile than amongst women in the highest quintile in Mongolia (75% versus 60%), while the
proportion of women in the highest income quintile reporting demand for family planning satisfied is higher than
the proportion of women in the lowest income quintile in Pakistan (59% versus 54%) and Viet Nam (77% versus
75%) (Figure 4.2). Evidence suggests that demand for family planning not satisfied is high amongst adolescents
and youth in Asia-Pacific countries and territories where the average age of marriage is low and gender
inequality is high (UNESCAP, 2018[3]).
References
UNESCAP (2018), Inequality in Asia and the Pacific in the era of the 2030 Agenda for Sustainable [3]
Development, United Nations Economic and Social Commission for Asia and the Pacific, Bangkok,
http://www.unescap.org/publications/inequality-asia-and-pacific-era-2030-agenda-sustainable-
development.
UNFPA (2019), State of World Population 2019: Unfinished business, United Nations Population Fund, [1]
New York, https://www.unfpa.org/sites/default/files/pub-
pdf/UNFPA_PUB_2019_EN_State_of_World_Population.pdf.
WHO/Johns Hopkins Bloomberg School of Public Health (2018), Family planning: a global handbook for [2]
providers: evidence-based guidance developed through worldwide collaboration,
https://apps.who.int/iris/handle/10665/260156.
Figure 4.1. Contraceptive prevalence, married or in-union women, latest available estimate
Any method Any modern method
%
100
75
50
25
Source: UN World Contraceptive Use 2021; DHS and MICS surveys, various years; and Bureau of Health, Macau (China), 2014.
StatLink 2 https://stat.link/o96k83
Figure 4.2. Demand for family planning satisfied by modern methods by socio-economic
characteristics, selected countries, latest year available
After the first six months of life, an infant needs additional nutritionally adequate and safe complementary foods,
while continuing breastfeeding. Appropriate complementary foods were introduced to around half of the children
between 6-8 months in India, whereas complementary foods were introduced to more than nine out of ten infants
in Sri Lanka, Thailand and Viet Nam (Figure 4.4).
Considering persisting high levels of childhood malnutrition (see indicator “Child malnutrition and overweight” in
Chapter 4), infant feeding practices must be further improved (UNICEF, 2019[1]).
References
Horta, B., V. Cesar and WHO (2013), Long-term effect of breastfeeding: a systemic review, World Health [2]
Organization, Geneva, https://apps.who.int/iris/handle/10665/79198.
Horta, B., C. Loret de Mola and C. Victora (2015), “Long-term consequences of breastfeeding on [3]
cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-
analysis”, Acta Paediatrica, Vol. 104, pp. 30-37, https://doi.org/10.1111/apa.13133.
Local Burden of Disease Exclusive Breastfeeding Collaborators (2021), “Mapping inequalities in exclusive [7]
breastfeeding in low- and middle-income countries, 2000–2018”, Nature Human Behaviour, Vol. 5/8,
pp. 1027-1045, https://doi.org/10.1038/s41562-021-01108-6.
OECD/WHO (2018), Health at a Glance: Asia/Pacific 2018: Measuring Progress towards Universal Health [9]
Coverage, OECD Publishing, Paris, https://doi.org/10.1787/health_glance_ap-2018-en.
Toolkits (2019), Bangladesh Breastmilk Substitutes (BMS) Act: Protecting, promoting, and supporting [8]
breastfeeding by ending the unethical marketing of BMS,
https://toolkits.knowledgesuccess.org/toolkits/breastfeeding-advocacy-toolkit/bangladesh-breastmilk-
substitutes-bms-act-protecting-promoting-and-supporting-breastfeeding-ending.
UNICEF (2021), United Nations Children’s Fund, The State of the World’s Children 2021: On My Mind – [6]
Promoting, protecting and caring for children’s mental health, UNICEF, New York,
https://www.unicef.org/media/114636/file/SOWC-2021-full-report-English.pdf.
UNICEF (2019), The State of the World’s Children. Children, Food and Nutrition: Growing well in a [1]
changing world., United Nations International Children’s Emergency Fund, New York,
http://www.unicef.org/media/63016/file/SOWC-2019.pdf.
Victora, C. et al. (2016), “Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect”, [4]
The Lancet, Vol. 387/10017, pp. 475-490, https://doi.org/10.1016/s0140-6736(15)01024-7.
WHO (2017), Guideline: protecting, promoting and supporting breastfeeding in facilities providing maternity [5]
and newborn services, World Health Organization, https://apps.who.int/iris/handle/10665/259386.
Figure 4.3. Infants exclusively breastfed, first Figure 4.5. Infants exclusively breastfed in
6 months of life, latest available year the first 6 months of life, by selected
socio-economic and geographic factors
Sri Lanka (2016) 81
Solomon Islands (2015) 76
Lowest education Highest education
DPRK (2017) 71
India (2020-21) 64 %
Bangladesh (2019) 63 100
Nepal (2019) 62
80
Papua New Guinea (2017) 60
Mongolia (2020) 58
60
Asia Pacific-LM/L 57
Philippines (2018) 55
40
Myanmar (2016) 51
Cambodia (2020-21) 51 20
Indonesia (2017) 51
Pakistan (2018) 48 0
Lao, PDR (2017) 44
Malaysia (2016) 40
Fiji (2004) 40
Asia Pacific-UM 29
Viet Nam (2014) 24
Lowest income quintile (poorest) Highest income quintile (richest)
China (2013) 21
%
Thailand (2019) 14
100
0 20 40 60 80 100
%
80
Source: UNICEF State of the world children 2021; India NHFS
2020-21. 60
StatLink 2 https://stat.link/d9q6x3
40
20 40
0 20
In 2018, almost 20 million overweight or obese children under age 5 lived in Asia (UNICEF, 2019[1]), and a high
prevalence of overweight (5.2%) was reported for Pacific Island countries (UNICEF/WHO/WB, 2021[6]). However,
the prevalence of childhood overweight varied across Asia-Pacific countries and territories. More than one child out
of ten was overweight in Australia, Papua New Guinea and Mongolia, whereas less than 2% of children under age 5
were overweight in Myanmar, Japan, and India (Figure 4.8). Nepal, Pakistan and Thailand reduced under 5
overweight rates since 2012, so they meet the Global Nutrition Target 2025 of no increase in childhood overweight
prevalence (WHO, 2020[7]). A low prevalence of overweight, however, did not always mean a proper nutrition intake
amongst children. For instance, a study in Nepal showed that children under age 2 were getting a quarter of their
energy intake from non-nutritive snacks and beverages such as biscuits or instant noodles (UNICEF, 2019[1]).
References
Development Initiatives (2018), Global Nutrition Report 2018: Shining a light to spur action on nutrition, [4]
Development Initiatives, Britsol, http://www.globalnutritionreport.org/reports/global-nutrition-report-2018/.
UNICEF (2019), The State of the World’s Children. Children, Food and Nutrition: Growing well in a [1]
changing world., United Nations International Children’s Emergency Fund, New York,
http://www.unicef.org/media/63016/file/SOWC-2019.pdf.
WHO (2020), Prevalence of overweight among children under 5 years of age (% weight-for-height >+2 SD), [7]
https://www.who.int/data/gho/data/indicators/indicator-details/GHO/children-aged-5-years-overweight-(-
weight-for-height-2-sd).
WHO (2020), The double burden of malnutrition: priority actions on ending childhood obesity, World Health [2]
Organization, Regional Office for South-East Asia., https://apps.who.int/iris/handle/10665/336266.
WHO (2017), Work programme of the United Nations Decade of Action on Nutrition (2016-2025), World [3]
Health Organization, https://apps.who.int/iris/handle/10665/259386.
WHO (2014), Global Nutrition Targets 2025: Childhood overweight policy brief, World Health Organization, [5]
https://apps.who.int/iris/handle/10665/149021.
Figure 4.6. Prevalence of stunting and wasting amongst children under age 5, latest year available
Stunting Wasting
%
50
40
30
20
10
Source: WHO GHO 2022; UNICEF 2021; DHS, MICS, and NHFS surveys, various years.
StatLink 2 https://stat.link/f4sdpz
Figure 4.7. Under-5 mortality and stunting Figure 4.8. Prevalence of overweight amongst
prevalence, latest year available children under age 5, latest year available
Stunting prevalence (%) Australia (2017-2018) 22.0
60
Papua New Guinea (2009-2011) 13.7
Mongolia (2018) 11.5
R² = 0.6223 Asia Pacific-H 10.5
50
Thailand (2015-2016) 9.8
PHL China (2013) 9.1
Brunei Darussalam (2009) 8.3
40
Indonesia (2013) 8.2
KHM Korea (2008-2011) 7.3
PAK SLB MNG
30 BRN Asia Pacific-UM 6.1
CHN KOR
LAO Viet Nam (2017) 6.0
LKA VNM
PNG Malaysia (2016) 5.9
MMR Fiji (2004) 5.1
20 NPL
MYS Solomon Island (2015) 4.9
IND SGP Asia Pacific-LM/L 4.5
10 Philippines (2018) 4.0
BGD
THA JPN Lao, PDR (2017) 3.5
IDN FJI
PRK Nepal (2016-17) 2.5
AUS Pakistan (2017-18) 2.4
0
0 10 20 30 40 50 60 70 Bangladesh (2019) 2.4
Under age 5 mortality (per 1 000 live births)
DPRK (2017) 2.3
Cambodia (2014) 2.2
Source: DHS and MICS surveys, various years; WHO GHO 2022;
Sri Lanka (2016) 2.0
UNICEF 2020; UN IGME; Childinfo 2019. India (2015-2016) 1.5
StatLink 2 https://stat.link/wr8jn0 Japan (2010) 1.5
Myanmar (2015-2016) 1.2
0 5 10 15 20 25
%
References
UNICEF/WHO (2019), Progress on household drinking water, sanitation and hygiene 2000-2017. Special [4]
Focus on INequalities, United Nations International Children’s Emergency Fund and World Health
Organization, New York,
https://www.unicef.org/media/55276/file/Progress%20on%20drinking%20water,%20sanitation%20and%
20hygiene%202019%20.pdf.
WHO (2018), Guidelines on Sanitation and Health, World Health Organization, [3]
https://apps.who.int/iris/handle/10665/274939.
Figure 4.8. Access to basic sanitation, 2020 and change between 2010-20
Urban Rural Urban Rural
2020 Change between 2010-20
Papua New Guinea
Solomon Islands
Mongolia
Bangladesh
Pakistan
Cambodia
Asia Pacific-LM/L
India
Lao, PDR
Myanmar
DPRK
Nepal
Indonesia
Philippines
Viet Nam
China
Sri Lanka
Asia Pacific-UM
Thailand
Fiji
New Zealand
Malaysia
Singapore
100 75 50 25 0 -10 0 10 20 30 40
% % point change
Figure 4.9. Access to basic drinking water, 2020 and change between 2010-20
Urban Rural Urban Rural
2020 Change between 2010-20
Papua New Guinea
Solomon Islands
Mongolia
Cambodia
Myanmar
Lao, PDR
Asia Pacific-LM/L
Indonesia
Pakistan
DPRK
India
Fiji
China
Malaysia
Nepal
Sri Lanka
Philippines
Asia Pacific-UM
Viet Nam
Bangladesh
Australia
New Zealand
Thailand
Brunei Darussalam
Singapore
Tobacco
Tobacco use is the leading global cause of preventable deaths and kills more than 8 million people each year,
of whom more than 7 million are from direct tobacco use and around 1.2 million are non-smokers exposed to
second-hand smoke. It is estimated that worldwide there were almost 1 billion current tobacco smokers
aged 15 years and above in 2020, 847 million of which were men. Amongst children between ages 13 and 15,
an estimated 24 million were smokers. Although global tobacco use has fallen over the past two decades, the
progress is still off track for achieving the target set by governments to cut tobacco use by 30% between 2010
and 2025 as part of the global efforts to reduce mortality from the four main non-communicable diseases
(cardiovascular diseases, cancer, chronic lung diseases and diabetes) (WHO, 2021[1]). The UN SDGs call for
strengthening the implementation of the World Health Organization Framework Convention on Tobacco Control
in all countries and territories, as appropriate.
Tobacco use is a major risk factor for six of the eight leading causes of premature mortality – ischemic heart
disease, cerebrovascular disease, lower respiratory infections, chronic obstructive pulmonary disease,
tuberculosis and cancer of the trachea, bronchus, and lung. Moreover, smoking in pregnancy can lead to low
birthweight and illness amongst infants (NCD Alliance, 2010[2]). Children who smoke in early adolescence also
increase their risk of cardiovascular diseases, respiratory illnesses, and cancer, and they are more likely to
experiment with alcohol and other drugs (CDC, 2021[3]). Smoking is also a risk factor for dementia. New studies
have shown that 14% of Alzheimer’s cases worldwide may be attributed to smoking (McKenzie, Batti and Tursan
d’Espaignet, 2014[4]; Livingston et al., 2017[5]). Recently, tobacco smoking is also found to be associated with
higher risks of developing severe symptoms and mortality amongst COVID-19 patients (WHO, 2020[6]; Vardavas
and Nikitara, 2020[7]). Smoking is harmful not only for smokers but also bystanders.
As of 2020, comprehensive smoke-free legislation was in place for almost 1.8 million people in 67 countries and
territories, covering only 23% of the world’s population. In Asia-Pacific, Australia, Brunei Darussalam, Cambodia,
Lao PDR, Nepal, New Zealand, Pakistan, Papua New Guinea and Thailand have comprehensive smoke-free
policies. Evidence shows that countries and territories with comprehensive smoke-free policies have decreased
the number of smokers and reduced mortality from smoking-related illnesses (WHO, 2021[1]).
The economic and social costs of tobacco use are also high, with families deprived of breadwinners who die
prematurely from tobacco-related diseases, large public health costs for treatment of tobacco-related diseases,
and lower workforce productivity (WHO, 2019[8]). Smoking rates in low-income countries are about half the rate
of rates in high-income countries (WHO, 2021[1]).
More than two in five men aged 15 and above in middle- and low-income Asia-Pacific countries and territories
reported current use of tobacco in 2020, as compared to one in four in high-income countries and territories
(Figure 4.11, left panel). The proportion of current tobacco users varied greatly across countries and territories.
This proportion amongst men was highest in Indonesia at 71.4%, and Myanmar, the Solomon Islands,
Papua New Guinea, Lao PDR, Bangladesh, and Mongolia, had over half of the adult males using tobacco
currently. New Zealand and Australia, however, reported the lowest prevalence, with around 15% of adult males
using tobacco currently. India has reduced smoking rates recently through implementation of multiple tobacco
control measures, including an innovative text message-based smoking cessation programme (WHO, 2019[8]).
However, India has a high prevalence of daily smokeless tobacco use amongst adults at 18.2% in 2018 (Global
Adult Tobacco Survey, https://www.who.int/tobacco/surveillance/survey/gats/GATS_India_2016-
17_FactSheet.pdf), and one in four adult men use smokeless tobacco daily.
There are large male-female disparities and 7.8%, 4.1% and 10.2% of women aged 15 and above report using
tobacco currently in high-, upper-middle-, and lower-middle- and low-income Asia-Pacific countries and
territories respectively (Figure 4.11, right panel). The rates were highest amongst female tobacco smokers in
Papua New Guinea (25.1%), Myanmar (19.7%), and the Solomon Islands (19.2%).
Tobacco use in adolescence has both immediate and long-term health consequences. Amongst youth aged 13 to
15 years, two in five males used tobacco in Papua New Guinea, and around one in four females used tobacco in
Papua New Guinea and Solomon Islands (Figure 4.12). In all reporting countries and territories, except for Nepal
and Fiji, the prevalence of tobacco use amongst females was higher for adolescents than adults. On the contrary,
the prevalence amongst males was higher for adults than for adolescents in all reporting countries and territories.
Increasing tobacco prices through higher taxes is an effective intervention to reduce tobacco use, by discouraging
youth from initiating tobacco use and encouraging tobacco users to reduce their consumption or quit (WHO, 2019[8])
Higher taxes also assist in generating additional government revenue. However, only New Zealand, Sri Lanka and
Thailand have total taxes that account for over 75% of the tobacco retail price in 2020 (WHO, 2021[1]). In Thailand,
increased tax revenue has been used to support smoking cessation programmes (WHO, 2019[8]). As a measure
of the comparative cost that current tobacco users in Asia-Pacific incur, in Nepal, Papua New Guinea and Sri
Lanka, around one fifth of the GDP per capita is required to purchase 2000 cigarettes of the most sold brand, while
this figure is of less than 2% of the GDP per capita in Japan, Korea and Singapore (Figure 4.13).
In Asia-Pacific, health warnings against tobacco use, including labels on tobacco product packaging and anti-
tobacco mass media campaigns to build public awareness, could be used more to reduce tobacco use. Australia,
Pakistan, Singapore and Thailand report that pictorial warning labels have effectively impacted smoking-related
behaviour. To increase the effectiveness of health warnings, Australia, New Zealand, Singapore (starting in
2020) and Thailand have mandated plain packaging of tobacco products (WHO, 2019[8]).
References
Livingston, G. et al. (2017), “Dementia prevention, intervention, and care”, The Lancet, Vol. 390/10113, [5]
pp. 2673-2734, https://doi.org/10.1016/S0140-6736(17)31363-6.
McKenzie, J., L. Batti and E. Tursan d’Espaignet (2014), WHO Tobacco Summaries: Tobacco and [4]
Dementia, World Health Organization, Geneva, https://www.who.int/publications-detail-redirect/WHO-
NMH-PND-CIC-TKS-14.1.
NCD Alliance (2010), Tobacco: a major risk factor for Non-communicable Diseases, [2]
https://ncdalliance.org/sites/default/files/rfiles/NCDA_Tobacco_and_Health.pdf.
Vardavas, C. and K. Nikitara (2020), “COVID-19 and smoking: A systematic review of the evidence”, [7]
International Society for the Prevention of Tobacco Induced Diseases, pp. 1-4,
https://doi.org/10.18332/tid/119324.
WHO (2021), WHO report on the global tobacco epidemic 2021: addressing new and emerging products, [1]
World Health Organization, https://apps.who.int/iris/handle/10665/343287.
WHO (2020), WHO statement: Tobacco use and COVID-19, http://www.who.int/news-room/detail/11-05- [6]
2020-who-statement-tobacco-use-and-covid-19.
WHO (2019), WHO report on the global tobacco epidemic, 2019: offer help to quit tobacco use, World [8]
Health Organization, https://apps.who.int/iris/handle/10665/326043.
Figure 4.11. Age-standardised prevalence estimates for current tobacco use amongst persons
aged 15 and above, by sex, 2020
Males Females
New Zealand
Australia
Asia Pacific-H
OECD
Singapore
Brunei Darussalam
Japan
Pakistan
DPRK
Fiji
Korea
Cambodia
Philippines
India
Thailand
Sri Lanka
Asia Pacific-UM
Malaysia
Viet Nam
Nepal
Asia Pacific-LM/L
China
Mongolia
Bangladesh
Lao PDR
Papua New Guinea
Solomon Islands
Myanmar
Indonesia
80 60 40 20 0 0 10 20 30
% %
StatLink 2 https://stat.link/03w4e2
Figure 4.12. Prevalence of current tobacco
use amongst youth aged 13 to 15, by sex,
latest available year Figure 4.13. Percentage of GDP per capita to
purchase 2000 cigarettes of the most sold
Females Males brand, latest available year
Papua New Guinea (2016) Nepal 21.9
Papua New Guinea 21.6
Malaysia (2017) Sri Lanka 19.0
Fiji 17.2
Solomon Islands (2011) India 13.8
Asia Pacific-LM/L 9.2
Myanmar (2016) Asia Pacific-UM 6.5
Philippines 6.0
Philippines (2015) Myanmar 5.8
Bangladesh 5.8
Indonesia 5.2
Thailand (2015) New Zealand 5.0
Malaysia 4.1
Mongolia (2019) Australia 3.9
Cambodia 3.3
Lao, PDR (2016) Lao, PDR 2.9
Thailand 2.7
Brunei Darussalam (2019) Viet Nam 2.6
Asia Pacific-H 2.6
Bangladesh (2014) OECD 2.3
China 2.1
Sri Lanka (2016) Mongolia 2.0
Singapore 1.7
Fiji (2016) Korea 1.2
Japan 1.2
Nepal (2015) 0 5 10 15 20 25
% GDP per capita
Cambodia (2016)
References
Dayrit, M. et al. (2018), The Philippines Health System Review, World Health Organization, Regional Office [4]
for South-East Asia, https://apps.who.int/iris/handle/10665/274579.
Harimurti, P., J. Prawira and K. Hort (2017), The Republic of Indonesia Health System Review, Health [5]
Systems in Transition, WHO Regional Office for South-East Asia,
https://apps.who.int/iris/handle/10665/254716.
Liu, X. and A. Zhu (2018), Attraction and Retention of Rural Primary Health-care Workers in the Asia Pacific [3]
Region, http://apps.who.int/iris/.
Muir, T. (2017), “Measuring social protection for long-term care”, OECD Health Working Papers, No. 93, [8]
OECD Publishing, Paris, https://doi.org/10.1787/a411500a-en.
Sakamoto, A., M. Rahman and S. Nomura (2018), Japan Health System Review, Health Systems in [2]
Transition, World Health Organization, Regional Office for South-East Asia,
https://apps.who.int/iris/handle/10665/259941.
Walton-Roberts, M. and S. Rajan (2020), “Global Demand for Medical Professionals Drives Indians Abroad [7]
Despite Acute Domestic Health-Care Worker Shortages”, Migration Information Source,
https://www.migrationpolicy.org/article/global-demand-medical-professionals-drives-indians-abroad.
WHO (2016), Global strategy on human resources for health: workforce 2030, World Health Organization, [1]
https://apps.who.int/iris/handle/10665/250368.
Figure 5.1. Doctors per 1 000 population, Figure 5.2. Nurses per 1 000 population,
latest year available latest year available
Mongolia (2018) 3.9 Australia (2019) 12.2
Australia (2019) 3.8 Japan (2018) 11.8
DPRK (2017) 3.7 New Zealand (2020) 10.6
OECD 3.6 OECD 9.6
New Zealand (2020) 3.4 Asia Pacific-H 8.1
Macau (China) (2020) 2.6 Korea (2019) 7.9
Asia Pacific-H 2.6 Singapore (2017) 6.2
Japan (2018) 2.5 Hong Kong (China) (2020) 6.2
Singapore (2019) 2.5 Brunei Darussalam (2018) 5.8
Korea (2019) 2.5 Philippines (2019) 4.6
Malaysia (2020) 2.3 DPRK (2017) 4.1
China (2019) 2.2 Mongolia (2018) 3.9
Hong Kong (China) (2020) 2.0 Macau (China) (2020) 3.8
Brunei Darussalam (2017) 1.6 Fiji (2019) 3.5
Asia Pacific-UM 1.6 Malaysia (2019) 3.4
Sri Lanka (2020) 1.2 Asia Pacific-UM 3.3
Pakistan (2019) 1.1 China (2019) 3.1
Asia Pacific-LM/L 1.1 Thailand (2019) 3.1
Thailand (2020) 1.0 Indonesia (2020) 2.3
Fiji (2015) 0.9 Solomon Islands (2018) 2.1
Nepal (2020) 0.9 Nepal (2020) 2.1
Viet Nam (2016) 0.8 Sri Lanka (2020) 2.1
Philippines (2020) 0.8 Asia Pacific-LM/L 1.8
Myanmar (2019) 0.7 India (2020) 1.7
India (2020) 0.7 Viet Nam (2016) 1.1
Bangladesh (2020) 0.7 Lao PDR (2020) 1.0
Indonesia (2020) 0.6 Myanmar (2019) 0.8
Lao PDR (2020) 0.4 Cambodia (2019) 0.6
Solomon Islands (2016) 0.2 Papua New Guinea (2019) 0.4
Cambodia (2014) 0.2 Bangladesh (2020) 0.4
Papua New Guinea (2019) 0.1 Pakistan (2019) 0.4
0 1 2 3 4 5 0 3 6 9 12 15
Per 1 000 population Per 1 000 population
10
8
6.3 6.0
6 4.8 4.7
4.1
3.6
4 3.2 3.2 3.2 3.1 3.1 3.0 3.0
2.7 2.7 2.5 2.5
2.1 1.9 1.7
1.7 1.5 1.4 1.4 1.4
2 1.1 1.0 1.0
0.6 0.4
Note: Denominator for Hong Kong (China) is based on mid-year population; for Macau (China) on end of year population.
Source: OECD Health Statistics 2022; WHO GHO, 2022; National Data Sources (see Annex A).
StatLink 2 https://stat.link/y3etcn
Figure 5.4. Doctor consultations per capita, Figure 5.5. Estimated number of
latest year available consultations per doctor, latest year available
Figure 5.6. Doctor consultations per capita and healthy life expectancy at birth, latest year available
Healthy life expectancy at birth, years
76
74 JPN
SGP
72 KOR
AUS
70 NZL
CHN
68 THA
LKA
66 BRN MYS
BGD VNM
64
62
KHM R² = 0.2697
MNG
60
0 3 6 9 12 15
Doctor consultations per capita
Source: OECD Health Statistics 2022; WHO GHO 2020; National Data Sources (see Annex A).
StatLink 2 https://stat.link/tvwbx6
Medical technologies
The need to prevent diseases, diagnose early and treat effectively under the Universal Health Coverage
mandate of the Sustainable Development Goals 3 calls for safe, effective, and appropriate medical care.
Medical technologies are crucial in the prevention, diagnosis and treatment of illness and diseases as well as
patient rehabilitation, but they also contribute to increases in health spending devices (WHO, 2017e). Computed
tomography (CT) scanners and magnetic resonance imaging (MRI) units help doctors diagnose a range of
conditions by producing images of internal organs and structures of the body. MRI exams do not expose patients
to ionising radiation, unlike conventional radiography and CT scanning. Mammography is used to diagnose
breast cancer, and radiation therapy units are used for cancer treatment. However, such equipment is expensive.
Data indicate that there are huge differences in availability of technologies across countries and territories, and
that the higher the country income level the higher the availability of medical equipment per million population
for all four selected medical equipment types.
Japan has by far the highest number of CT scanners per million population. More than 115 CT scanners are
available per million population in Japan, as opposed to less than one per million population in Bangladesh,
Pakistan, Papua New Guinea, Lao PDR and Myanmar (Figure 5.7). Also for MRI units, Japan reports 55 units
per million population, whereas Cambodia, Myanmar, Pakistan, the Philippines, Sri Lanka and Bangladesh,
report less than one unit per million population (Figure 5.8) Korea has the highest number of mammographs at
421.9 per million females aged 50-69, as opposed to Bangladesh, Pakistan, Myanmar, Sri Lanka and Papua
New Guinea, where less than 10 mammographs are available per million females aged 50-69 (Figure 5.9).
There is no general guideline or benchmark regarding the ideal number of CT scanners or MRI units per
population. However, if there are too few units, this may lead to access problems in terms of geographic proximity
or waiting times. If there are too many, this may result in an overuse of these costly diagnostic procedures, with
little if any benefits for patients. Although there is limited evidence on the use of medical technologies in the
Asia-Pacific region, data from OECD countries show that several countries with a high number of CT scanners
and MRIs, such the United States, also have a higher number of diagnostic exams per population, suggesting
some degree of overuse (OECD, 2017[1]).
The availability of treatment equipment is also much higher in high-income countries. Australia and Japan have
over 10 radiation therapy units per million population, whereas there is less than one unit per 10 million people
in Papua New Guinea, Cambodia, Bangladesh, Lao PDR, Indonesia, Pakistan, Nepal, Viet Nam, Myanmar, the
Philippines and India (Figure 5.10).
Clinical guidelines have been developed in some OECD countries to promote more rational use of diagnostic
technologies (OECD, 2017[1]). In the United Kingdom, the National Institute for Health and Clinical
Excellence (NICE) has issued a number of guidelines on the appropriate use of MRI and CT exams (NICE,
2020[2])e. In Australia, a “Choosing Wisely” campaign has developed clear guidelines for doctors and patients
to reduce the use of unnecessary diagnostic tests and procedures. The guidelines include, for instance, avoiding
imaging studies such as MRI, CT or X-rays for acute low back pain without specific indications (Choosing Wisely
Australia, 2020[3]). In Australia, clinicians may use Diagnostic Imaging Pathways (DIP), an evidence-based
clinical decision support tool and educational resource for diagnostic imaging. DIP guides the choice of the most
appropriate diagnostic examinations in the correct sequence in a wide range of clinical scenarios. The broad
objective is to reduce the number of unnecessary examinations that may expose patients to risk without benefits,
and increase the number of appropriate examinations resulting in cost-effective diagnosis (Government of
Western Australia, 2020[4]).
References
NICE (2020), NICE guidance, National Institute for Health and Care Excellence, http://nice.org.uk. [2]
OECD (2017), Tackling Wasteful Spending on Health, OECD Publishing, Paris, [1]
https://doi.org/10.1787/9789264266414-en.
Figure 5.7. Computed tomography scanners, Figure 5.8. MRI units, latest year available
latest year available
0 50 100 150 0 20 40 60
Per million population Per million population
Source: OECD Health Statistics 2022; WHO Global atlas of Source: OECD Health Statistics 2022; WHO Global atlas of
medical devices 2022 (forthcoming). medical devices 2022 (forthcoming).
StatLink 2 https://stat.link/uypzv6 StatLink 2 https://stat.link/j1l6qv
Figure 5.9. Mammographs, latest year Figure 5.10. Radiation therapy equipment,
available latest year available
Source: OECD Health Statistics 2022; WHO Global atlas of Source: OECD Health Statistics 2022; WHO Global atlas of
medical devices 2022 (forthcoming). medical devices 2022 (forthcoming).
StatLink 2 https://stat.link/glemor StatLink 2 https://stat.link/y2zl93
Hospital care
Hospitals in most countries and territories account for the largest part of health care expenditure. Capacity of
the hospital sector and access to hospital care are assessed in this report by the number of hospital beds and
hospital discharge rates. However, increasing the numbers of beds and overnight stays in hospitals does not
always bring positive outcomes as resources need to be used efficiently. Hence, the average length of
stay (ALOS) is also used to assess appropriate access to and use of hospital care, but caution is needed in its
interpretation. Although, all other things being equal, a shorter stay will reduce the cost per discharge and provide
care more efficiently by possibly shifting care from inpatient to less expensive post-acute settings, too short a
length of stay may reduce the comfort and hamper the recovery of the patient or increase hospital readmissions.
The number of hospital beds is 2.6 and 2.8 per 1 000 population on average across upper-middle and lower-
middle and low-income Asia-Pacific countries and territories, respectively; lower than the OECD average of 4.6
and the high-income Asia-Pacific countries and territories average of 5.4 (Figure 5.11). More than one bed per
100 population is available in DPRK, Korea and Japan, whereas the stock of beds is less than one per 1 000
population in India, Pakistan, Bangladesh and Cambodia. These large disparities reflect substantial differences
in the resources invested in hospital care across countries and territories.
Hospital discharge is at 121.3 and 130 per 1 000 population on average in upper-middle and lower-middle and
low-income Asia-Pacific countries and territories, respectively; close to the OECD average of 130.6
(Figure 5.12). The highest rates are in Sri Lanka and Mongolia, with over 275 discharges per 1 000 population
in a year, while in Bangladesh, Cambodia and Nepal, discharge rates are less than 50 per 1 000 population,
suggesting deferrals in accessing hospital services.
In general, countries and territories with more hospital beds tend to have higher discharge rates, and vice versa
(Figure 5.13). However, there are some notable exceptions. Korea and Japan, with the second and third highest
number of hospital beds per population, respectively, have relatively low discharge rates; while Sri Lanka, with
a close-to-average hospital beds availability for the region, has the highest discharge rate.
In Asia-Pacific, the variation across countries and territories in the number of days spent – on average – in
hospital is large (Figure 5.14). Lower-middle- and low-income countries and territories report the lowest ALOS
in Asia-Pacific at 4.9 days. The longest average length of stay is of more than 16 days in Japan, while the
shortest length of stay is 2.5 days in Lao PDR and Bangladesh. In Japan, “social admission”, in that some “acute
care” beds are devoted to long-term care for the elderly, partly explains the large number of beds and long ALOS
(Sakamoto, Rahman and Nomura, 2018[1]). A short ALOS, coupled with the high admission rates in Sri Lanka,
suggests that inpatient services may be partly substituting for outpatient and primary care.
References
Sakamoto, A., M. Rahman and S. Nomura (2018), Japan Health System Review, Health Systems in [1]
Transition, World Health Organization, Regional Office for South-East Asia,
https://apps.who.int/iris/handle/10665/259941.
Figure 5.11. Hospital beds per 1 000 Figure 5.12. Hospital discharges per 1 000
population, latest year available population, latest year available
DPRK (2010) 14.3 Sri Lanka (2019) 345
Korea (2020) 12.7
Japan (2020) 12.6 Mongolia (2017) 276
Mongolia (2017) 8.0 Hong Kong (China) (2020) 252
Asia Pacific-H 5.4
China (2020) 5.0 China (2019) 182
OECD 4.6 Australia (2019) 174
Hong Kong (China) (2020) 4.1 Korea (2020) 154
Sri Lanka (2019) 4.0
Australia (2016) 3.8 New Zealand (2019) 146
Brunei Darussalam (2020) 2.9 Asia Pacific-H 144
Asia Pacific-LM/L 2.8 Thailand (2018) 144
New Zealand (2021) 2.7
Viet Nam (2014) 2.6 Japan (2017) 134
Asia Pacific-UM 2.6 OECD 131
Macau (China) (2020) 2.5 Asia Pacific-LM/L 130
Thailand (2018) 2.1
Fiji (2017) 2.0 Asia Pacific-UM 121
Singapore (2020) 2.0 Singapore (2018) 104
Lao PDR (2012) 1.5 Brunei Darussalam (2020) 100
Solomon Islands (2012) 1.4
Malaysia (2019) 1.3 Macau (China) (2019) 92
Nepal (2016) 1.2 Malaysia (2019) 86
Myanmar (2017) 1.0
Indonesia (2017) 1.0 Fiji (2017) 73
Philippines (2014) 1.0 Myanmar (2016) 52
Cambodia (2016) 0.9 Nepal (2019/20) 42
Bangladesh (2019) 0.9
Pakistan (2017) 0.6 Cambodia (2011) 41
India (2017) 0.5 Bangladesh (2011) 24
0 4 8 12 16 0 50 100 150 200 250 300 350 400
Per 1 000 population Per 1 000 population
Source: OECD Health Statistics 2022; WHO GHO 2020, Source: OECD Health Statistics 2022; National sources (see
Hong Kong annual statistic digest 2021, National sources (see Annex A).
Annex A). StatLink 2 https://stat.link/ldaf3b
StatLink 2 https://stat.link/65m3na
Figure 5.13. Hospital beds per 1 000 Figure 5.14. Average length of stays for acute
population and hospital discharges per 1 000 care in hospitals, latest year available
population, latest year available
Japan (2020) 16.4
China (2018) 9.3
Hospital discharges, per 1 000 population Brunei Darussalam (2020) 8.0
400 Mongolia (2011) 7.9
Korea (2020) 7.8
350 Macau (China) (2020) 7.8
LKA Asia Pacific-H 7.4
India (2014) 6.8
300 Viet Nam (2003) 6.7
MNG OECD 6.5
250 HKG Fiji (2011) 6.0
Papua New Guinea (2008) 6.0
Asia Pacific-UM 5.8
200 Myanmar (2016) 5.1
AUS CHN Cambodia (2011) 5.0
Singapore (2013) 5.0
150 THA NZL KOR
Philippines (2012)
OECD JPN 4.9
Asia Pacific-LM/L 4.9
SGP
100 MYS BRN New Zealand (2019) 4.7
MAC Australia (2019) 4.7
FJI R² = 0.188 Hong Kong (China) (2010) 4.7
50 MMR
KHM Indonesia (2011) 4.4
NPL Malaysia (2019) 4.1
BGD Thailand (2009) 4.0
0
Sri Lanka (2017) 3.5
0 2 4 6 8 10 12 14 Nepal (2019/20)
Hospital beds, per 1 000 population 3.0
Bangladesh (2017) 2.5
Lao PDR (2012) 2.5
0 5 10 15 20
Source: OECD Health Statistics 2022; WHO GHO 2022. Days
StatLink 2 https://stat.link/sjpe57 Source: OECD Health Statistics 2022; National data sources (see
Annex A).
StatLink 2 https://stat.link/08h6bc
References
WHO (2016), WHO recommendations on antenatal care for a positive pregnancy experience, World Health [1]
Organization, https://apps.who.int/iris/handle/10665/250796.
Figure 5.15. Provision of care during pregnancy and birth, 2021 or latest year available
At least 4 antenatal visits during last pregnancy Births attended by skilled health personnel
Malaysia
Korea
Asia Pacific-H
DPRK
OECD
Brunei Darussalam
China
Sri Lanka
Asia Pacific-UM
Australia
Thailand
Fiji
Mongolia
Viet Nam
Philippines
Nepal
Indonesia
Cambodia
Asia Pacific-LM/L
Solomon Islands
Lao PDR
Myanmar
India
Pakistan
Papua New Guinea
Bangladesh
Japan
New Zealand
Singapore
100 80 60 40 20 0 0 20 40 60 80 100
% %
Note: Women included are aged 15-49.
Source: UNICEF 2022.
StatLink 2 https://stat.link/nacobx
Figure 5.16. Place of delivery, latest year Figure 5.17. Births attended by skilled health
available professionals, by socio-economic and
geographic factors, latest year available
Other/Missing Private facility Public facility Home
% Lowest education Highest education
100 Rural Urban
Lowest income Highest income
Myanmar (2015-16)
60 Lao PDR (2017)
Mongolia (2018)
40 Thailand (2019)
20 Pakistan (2017-18)
Nepal (2019)
0 DPRK (2017)
Bangladesh (2019)
0 20 40 60 80 100
% of skilled birth attendance by socio-economic factors
Source: DHS and MICS surveys, various years. Source: DHS and MICS surveys, various years.
StatLink 2 https://stat.link/xyhpls StatLink 2 https://stat.link/8ydqjb
References
Bhutta, Z. et al. (2013), “Interventions to address deaths from childhood pneumonia and diarrhoea [1]
equitably: What works and at what cost?”, The Lancet, Vol. 381/9875, pp. 1417-1429,
https://doi.org/10.1016/S0140-6736(13)60648-0.
Figure 5.18. Children aged 6-59 months who Figure 5.19. Children aged under 5 years with
received full dose vitamin A supplementation, diarrhoea receiving oral rehydration solution
latest year available and zinc supplements, latest year available
Bangladesh (2020) 97 DPRK (2017) 45
0 20 40 60 80 100 0 20 40 60 80 100
% %
Source: UNICEF 2012; DHS and MICS surveys, various years. Source: DHS and MICS surveys, various years.
StatLink 2 https://stat.link/r1me7i StatLink 2 https://stat.link/obis65
Figure 5.20. Children aged under 5 years with Figure 5.21. Care seeking and antibiotic
diarrhoea receiving continued feeding and treatment among children aged under 5 years
oral rehydration therapy, latest year available with acute respiratory infection, latest year
available
Mongolia (2018) 71
Taken to a health facility
DPRK (2017) 71 With antibiotic treatment
Source: UNICEF 2021; NHFS, DHS and MICS surveys, various Note: First year refers to children taken to a health facility, the
years. second year refers to those who received antibiotic treatment.
StatLink 2 https://stat.link/vhwqpk Source: UNICEF 2021, NHFS, DHS and MICS surveys, various years.
StatLink 2 https://stat.link/3l56sp
There are 7.5 and 19.9 mental health beds per 100 000 population on average in lower-middle- and low-income,
and upper-middle-income Asia-Pacific countries and territories, respectively, with Bangladesh, Papua New
Guinea and Nepal reporting less than two psychiatric beds per 100 000 population (Figure 5.24). The large
majority of beds in middle- and low-income countries and territories are available in mental health hospitals.
References
Australian Department of Health and Ageing (2012), Evaluation of the Mental Health Nurse Incentive [3]
Program Final Report.
Australian Institute of Health and Welfare (2019), Mental health services - in brief 2019. [2]
WHO (2018), Mental health atlas 2017, World Health Organization, [1]
https://apps.who.int/iris/handle/10665/272735.
WHO (2016), mhGAP intervention guide for mental, neurological and substance use disorders in non- [4]
Specialized health settings : mental health gap action programme (mhGAP), World Health Organization,
https://apps.who.int/iris/handle/10665/44406.
Figure 5.22. Psychiatrists, per 100 000 Figure 5.23. Nurses working in mental health
population, 2020 or latest year available sector, per 100 000 population, 2020 or latest
year available
Source: OECD Health Statistics 2022; WHO Mental Health Atlas Source: OECD Health Statistics 2022; WHO Mental Health Atlas
2020. 2020.
StatLink 2 https://stat.link/wkbvh5 StatLink 2 https://stat.link/70if6y
Figure 5.24. Mental health beds, per 100 000 population, 2020 or latest year available
200
150
100
50
Source: OECD Health Statistics 2022; WHO Mental Health Atlas 2020.
StatLink 2 https://stat.link/q957hc
References
OECD (2019), Health for Everyone?: Social Inequalities in Health and Health Systems, OECD Health Policy [2]
Studies, OECD Publishing, Paris, https://doi.org/10.1787/3c8385d0-en.
Thummapol, O., T. Park and S. Barton (2018), “Exploring health services accessibility by indigenous [1]
women in Asia and identifying actions to improve it: a scoping review”, Ethnicity & Health,
Vol. 25/7, pp. 940-959, https://doi.org/10.1080/13557858.2018.1470607.
Figure 5.25. Women aged 15-49 who reported Figure 5.26. Women aged 15-49 who reported
problems in accessing care due to financial problems in accessing care due to distance,
reasons, by socio-economic characteristics, by socio-economic characteristics, latest
latest year available year available
% %
100 100
80 80
60 60
40 40
20 20
0
0
40
40
20 20
0 0
% %
100 100
80
80
60
60
40
20 40
0 20
Source: DHS surveys, various years. Source: DHS surveys, various years.
StatLink 2 https://stat.link/ng8sfq StatLink 2 https://stat.link/jrzcln
To make useful comparisons of real growth rates over time, it is necessary to deflate (i.e. remove inflation
from) nominal health expenditure using a suitable price index, and also to divide by the population, to derive
real spending per capita. Due to the limited availability of reliable health price indices, an economy-wide
(GDP) price index is used in this publication.
The annual average growth rate was computed using a geometric growth rate formula:
Gross fixed capital formation in the health sector is measured by the total value of the fixed assets that health
providers have acquired during the accounting period (less the value of the disposals of assets) and that are
used repeatedly or continuously for more than one year in the production of health services. The breakdown
by assets includes infrastructure (e.g. hospitals, clinics), machinery and equipment (including diagnostic and
surgical machinery, ambulances, and ICT equipment), as well as software and databases. Gross fixed capital
formation is reported by many countries under the System of Health Accounts.
Note
1
A break in series for Japan in 2011 contributes to this result.
Figure 6.1. Health expenditure per capita, Figure 6.2. Annual average growth rate in per
2019 capita health expenditure and GDP, real
terms, 2010-19
Government/Compulsory Voluntary/Out-of-pocket Health expenditure (%)
10
Australia CHN
Japan
New Zealand
OECD
Singapore 8
Asia Pacific-H SLB
Korea
Brunei Darussalam KOR
Malaysia MYS MNG
China 6
SGP KHM
Asia Pacific-UM LKA
Thailand PAK FJI BGD
Sri Lanka IND
Viet Nam THA IDN PHL LAO
4
Fiji NPL
JPN
Mongolia PNG
Philippines
Indonesia AUS
Cambodia 2
Asia Pacific-LM/L NZL
Myanmar
Lao PDR
India 0
Nepal
Pakistan BRN
Bangladesh
Papua New Guinea
-2
0 1000 2000 3000 4000 5000 6000 -2 0 2 4 6 8 10
USD PPP
GDP (%)
Source: WHO Global Health Expenditure Database; OECD Health Source: WHO Global Health Expenditure Database.
Statistics 2022. StatLink 2 https://stat.link/xg2ij9
StatLink 2 https://stat.link/3m76kn
Figure 6.3. Change in health expenditure as a Figure 6.4. Gross fixed capital formation in
share of GDP, 2010-19 the health care sector as a share of GDP,
2019
JPN Philippines
AUS
NZL China
KOR
AP-H Australia¹
CHN Papua New Guinea
VNM Increase
MMR Mongolia
AP-UM Little change
SGP Korea
LKA Decrease Nepal
MYS
FJI Singapore¹
THA Pakistan¹
PAK
PNG Sri Lanka¹
OECD
KHM Myanmar
PHL NPL Fiji
AP-LM/L Thailand
MNG Indonesia
IDN
BRN Malaysia
IND
LAO Lao PDR
BGD
Brunei Darussalam
0 2 4 6 8 10 12 0.0 0.2 0.4 0.6
% %
Source: WHO Global Health Expenditure Database; OECD Health 1. Data refer to 2018.
Statistics 2022. Source: WHO Global Health Expenditure Database.
StatLink 2 https://stat.link/0uj5lq StatLink 2 https://stat.link/t9akf2
References
OECD/WHO/Eurostat (2011), A System of Health Accounts: 2011 Edition, OECD Publishing, Paris, [1]
https://doi.org/10.1787/9789264116016-en.
Note
1
A break in series in 2011 contributes to this result.
Figure 6.5. Health expenditure by government scheme and compulsory insurance scheme as a
share of health expenditure, 2010 and 2019
% of health expenditure
100
90 Increase
80
70 Little change
60 Decrease
50
40
30
20
10
0
Source: WHO Global Health Expenditure Database; OECD Health Statistics 2022.
StatLink 2 https://stat.link/0i3cgl
Figure 6.6. Health expenditure by government scheme and compulsory insurance scheme as a
share of GDP, 2010 and 2019
% of GDP
10
9 Increase
8
Little change
7
6 Decrease
5
4
3
2
1
0
Source: WHO Global Health Expenditure Database; OECD Health Statistics 2022.
StatLink 2 https://stat.link/pxribn
Figure 6.7. Health expenditure by government and compulsory health insurance schemes as a
share of total government expenditure, 2010 and 2019
% of total government expenditure
30
Increase
25
Little change
20
Decrease
15
10
5
0
Source: WHO Global Health Expenditure Database; OECD Health Statistics 2022.
StatLink 2 https://stat.link/h4i618
References
OECD/WHO/Eurostat (2011), A System of Health Accounts: 2011 Edition, OECD Publishing, Paris, [3]
https://doi.org/10.1787/9789264116016-en.
Wang, H., L. Torres and P. Travis (2018), “Financial protection analysis in eight countries in the WHO [1]
South-east Asia region”, Bulletin of the World Health Organization, Vol. 96/9,
https://doi.org/10.2471/BLT.18.209858.
WHO/World Bank (2019), Global Monitoring Report on Financial Protection in Health 2019, World Health [2]
Organization, https://apps.who.int/iris/handle/10665/331748.
Figure 6.8. Health expenditure by households’ out-of-pocket as a share of health expenditure, 2010
and 2019
% of health expenditure
90
80 Increase
70 Little change
60
Decrease
50
40
30
20
10
0
Source: WHO Global Health Expenditure Database; OECD Health Statistics 2022.
StatLink 2 https://stat.link/u6q290
Figure 6.9. Health expenditure by voluntary health care payment schemes as a share of health
expenditure, 2010 and 2019
% of health expenditure
25
Increase
20
Little change
15 Decrease
10
Source: WHO Global Health Expenditure Database; OECD Health Statistics 2022.
StatLink 2 https://stat.link/8sydpg
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Figure 6.11. Domestic general government health expenditure by type of service, 2019
Curative and rehabilitative care Long-term care (health) Ancillary services
Medical goods Preventive care Administration and other health care services
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Sri Lanka Viet Nam China Pakistan Malaysia Thailand Indonesia India Myanmar Fiji Cambodia Japan Korea Lao PDR Nepal
(2018)
7 Quality of care
Childhood vaccination
Childhood vaccination continues to be one of the most cost-effective health policy interventions, preventing 4 to
5 million deaths every year (WHO, 2019[1]). Nevertheless, the global coverage for three doses of diphtheria-
tetanus-pertussis (DTP3) vaccine dropped from 86% in 2019 to 81% in 2021 and an estimated 25 million children
under the age of 1 year did not receive basic vaccines, the highest number since 2009 (WHO, 2020[2]).
All countries and territories in Asia-Pacific have established vaccination programmes including a minimum
number of routine vaccines (i.e. against polio, diphtheria, tetanus, pertussis, measles); additional vaccines
(i.e. against pneumococcus, rotavirus, Japanese encephalitis and human papilloma virus) are included at
national or subnational level based on local morbidity, mortality and cost-effectiveness analysis.
Health systems providing high quality of care deliver effective, safe and people-centred health care. These
national and subnational vaccination programmes are effective and safe in reducing disease burden of the
population, and the level of adherence to the guidelines on childhood vaccination also reflects importantly the
quality of care provided in countries, as well as availability, accessibility and affordability of vaccination services.
Diphtheria tetanus toxoid and pertussis, measles and hepatitis B vaccines are taken here as examples as they
represent, in timing and frequency of vaccination, the full spectrum of organisational challenges related to routine
vaccination for children. Pertussis, known as whooping cough, is a respiratory infection caused by
bacteria. Immunisation is the most effective way of preventing infection. Three doses of pertussis vaccine,
together with diphtheria and tetanus toxoid reduces the risk of severe pertussis among infants. WHO
recommends the administration of the first dose as early as 6 weeks of age, subsequent doses given at least
4 weeks apart, and the third dose of the primary series should be completed by 6 months of age, if possible
(WHO, 2020[3]). Measles is a highly contagious viral disease. The measles vaccine is not only safe and effective,
but also inexpensive. Although vaccination has substantially reduced global measles deaths and the estimated
number of deaths decreased by 62% between 2000 and 2019, measles is still common in many developing
countries and measles incidence has increased globally including in Asia since 2016 (Patel et al., 2020[4]). WHO
recommends measles immunisation to all susceptible children, adolescents and adults if not contraindicated.
Two doses of measles vaccine, either alone, or combined with rubella, and/or mumps, should be the standard
for national childhood immunisation programmes (WHO, 2020[5]). Vaccination for hepatitis B is considered
effective in preventing infection and its chronic consequences, such as cirrhosis and liver cancer. Yet, in 2019,
hepatitis B resulted in 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma. Globally, WHO
Western Pacific is the region with most infections in the world, and 116 million people are chronically infected
(WHO, 2022[6]). Hepatitis B vaccination is recommended for all children, and at least three doses of hepatitis B
vaccine should be the standard for national immunisation programmes (WHO, 2021[7]).
Reviews of the evidence supporting the efficacy of vaccines included in routine immunisation programmes have
concluded that they are safe and highly effective against mortality and morbidity caused by the diseases
concerned. Hence, high coverage of these programmes illustrates effective delivery of high-quality health care.
The COVID-19 pandemic, however, impeded access to childhood vaccinations in many countries as these
services had been scaled down or closed, or people were concerned about risks of COVID-19 infection (WHO,
2020[2]). Consequently, vaccination rates have not returned to the pre-pandemic period in about half of the
countries in the Asia-Pacific region (see Chapter 2 “The health impact of COVID-19”).
In 2021, the overall vaccination of children against pertussis (provided through combined vaccines containing
diphtheria and tetanus), measles and hepatitis B was high in most Asia-Pacific countries. In most high and
upper-middle-income Asia-Pacific countries, almost all children aged around one year received the
recommended measles, DTP3 and hepatitis B vaccination, meeting the WHO’s minimum threshold of 95% to
avoid vaccine-preventable diseases outbreaks. On the contrary, the average vaccination rate in lower-middle
and low-income Asia-Pacific countries for these diseases was around 75%, which is insufficient to ensure
interruption of disease transmission and protection of the whole population (Figures 7.1, 7.2 and 7.3). The
average rate for these countries in 2021 was about 10 percentage points lower than the average rate in 2019
(European Commission, 2017[8]; OECD/WHO, 2020[9]), suggesting a substantial negative impact of COVID-19
pandemic on vaccination programmes.
Vaccination coverage rates for DTP3, measles and hepatitis B were similar for each Asia-Pacific country. Brunei
Darussalam and China had the highest rate in Asia-Pacific at 99% against all of them. However, in Papua New
Guinea, Myanmar and DPRK, less than one in two children were vaccinated with all three (Figures 7.1, 7.2
and 7.3).
References
European Commission (2017), Cancer Screening in Report on the implementation of the Council [8]
Recommendation on cancer screening,
https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndr
eportimplementation_en.pdf.
OECD/WHO (2020), Health at a Glance: Asia/Pacific 2020: Measuring Progress Towards Universal Health [9]
Coverage, OECD Publishing, Paris, https://doi.org/10.1787/26b007cd-en.
Patel, M. et al. (2020), “Progress Toward Regional Measles Elimination — Worldwide, 2000–2019”, [4]
MMWR. Morbidity and Mortality Weekly Report, Vol. 69/45, pp. 1700-1705,
https://doi.org/10.15585/mmwr.mm6945a6.
WHO (2021), WHO recommendations for routine immunization - summary tables, World Health [7]
Organization, https://cdn.who.int/media/docs/default-
source/immunization/immunization_schedules/immunization-routine-table1.pdf.
WHO (2020), Vaccines work at all ages, everywhere, World Health Organization, http://www.who.int/news- [2]
room/commentaries/detail/vaccines-work-at-all-ages-everywhere.
Figure 7.1. Vaccination coverage for diphtheria, tetanus toxoid and pertussis-containing vaccine,
third dose (DTP3), 2021
% of children vaccinated
100
90
80
70
60
50
40
30
20
99
99
99
98
98
98
97
96
96
96
96
95
95
95
92
91
90
87
87
85
83
83
75
75
67
57
41
37
31
10
0
Figure 7.2. Vaccination coverage for measles-containing vaccine, first dose (MCV1), 2021
% of children vaccinated
100
90
80
70
60
50
40
30
20
99
99
98
98
97
97
97
96
96
96
96
95
95
93
91
90
89
89
86
84
81
74
73
72
67
57
44
42
38
10
0
Figure 7.3. Vaccination coverage for hepatitis B-containing vaccine, third dose (HepB3), 2021
% of children vaccinated
100
90
80
70
60
50
40
30
20
99
99
99
98
98
97
97
96
96
95
95
95
94
92
92
91
90
87
87
85
83
83
75
75
67
57
41
37
31
10
0
References
Gil, M. et al. (1999), “Relationship of Therapeutic Improvements and 28-Day Case Fatality in Patients [2]
Hospitalized With Acute Myocardial Infarction Between 1978 and 1993 in the REGICOR Study, Gerona,
Spain”, Circulation, Vol. 99/13, pp. 1767–1773, https://doi.org/10.1161/01.CIR.99.13.1767.
Lalloué, B. et al. (2019), “Does size matter? The impact of caseload and expertise concentration on AMI 30- [7]
day mortality—A comparison across 10 OECD countries”, Health Policy, Vol. 123/5, pp. 441-448,
https://doi.org/10.1016/j.healthpol.2019.03.007.
OECD (2019), Health at a Glance 2019: OECD Indicators, OECD Publishing, Paris, [6]
https://doi.org/10.1787/4dd50c09-en.
OECD (2015), Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care, OECD [3]
Health Policy Studies, OECD Publishing, Paris, https://doi.org/10.1787/9789264233010-en.
OECD (2015), OECD Reviews of Health Care Quality: Japan 2015: Raising Standards, OECD Reviews of [5]
Health Care Quality, OECD Publishing, Paris, https://doi.org/10.1787/9789264225817-en.
Tam, C. et al. (2020), “Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment– [4]
Elevation Myocardial Infarction Care in Hong Kong, China”, Circulation: Cardiovascular Quality and
Outcomes, Vol. 13/4, https://doi.org/10.1161/circoutcomes.120.006631.
Zhao, D. (2021), “Epidemiological Features of Cardiovascular Disease in Asia”, JACC: Asia, Vol. 1/1, pp. 1- [1]
13, https://doi.org/10.1016/j.jacasi.2021.04.007.
Figure 7.4. In-hospital case-fatality rates within 30 days after admission for acute myocardial
infarction, patients 45 years old and over, 2009 and 2019 (or nearest years)
2009 2019
Age-sex standardised rate per 100 admissions aged 45 years and over
15
10
10.7
9.7
8.9
5 7.4
6.6
4.3
0 3.2
Figure 7.5. In-hospital case-fatality rates within 30 days after admission for ischemic stroke,
patients 45 years old and over, 2009 and 2019 (or nearest years)
2009 2019
Age-sex standardised rate per 100 admissions aged 45 years and over
15
10
5 7.7
6.5
4.7 4.9 5.4
3.0 3.5
0
Figure 7.6. In-hospital case-fatality rates within 30 days after admission for haemorrhagic stroke,
patients 45 years old and over, 2009 and 2019 (or nearest years)
2009 2019
Age-sex standardised rate per 100 admissions aged 45 years and over
35
30
25
20
15 19.9 20.9 21.5
17.3 18.4
10 15.5
5
0
References
Allemani, C. et al. (2018), “Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): [11]
analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322
population-based registries in 71 countries”, The Lancet, Vol. 391/10125, pp. 1023-1075,
https://doi.org/10.1016/S0140-6736(17)33326-3.
González-Jiménez, E. et al. (2014), “Breastfeeding and the prevention of breast cancer: a retrospective [2]
review of clinical histories”, Journal of Clinical Nursing, Vol. 23/17-18, pp. 2397-2403,
https://doi.org/10.1111/jocn.12368.
IARC (2022), Cancer Over Time, International Agency for Research on Cancer, Lyon, [3]
https://gco.iarc.fr/overtime/en.
IARC (2022), Cancer Today, International Agency for Research on Cancer, Lyon, https://gco.iarc.fr/today/. [4]
IARC (2016), Breast Cancer Screening, IARC Handbooks of CAncer Prevention, No. 15, International [6]
Agency for Research on Cancer, Lyon, https://publications.iarc.fr/Book-And-Report-Series/Iarc-
Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016.
OECD (2021), Health at a Glance 2021: OECD Indicators, OECD Publishing, Paris, [7]
https://doi.org/10.1787/ae3016b9-en.
OECD (2013), Cancer Care: Assuring Quality to Improve Survival, OECD Health Policy Studies, OECD [5]
Publishing, Paris, https://doi.org/10.1787/9789264181052-en.
Pg Suhaimi, A. et al. (2020), “Predictors of non-communicable diseases screening behaviours among adult [14]
population in Brunei Darussalam: a retrospective study”, Journal of Public Health, Vol. 29/6, pp. 1303-
1312, https://doi.org/10.1007/s10389-020-01240-z.
Pham, T. et al. (2019), “Cancers in Vietnam—Burden and Control Efforts: A Narrative Scoping Review”, [9]
Cancer Control, Vol. 26/1, https://doi.org/10.1177/1073274819863802.
Wahidin, M. (2018), “Overview of Ten Years (2007-2016) Cervical and Breast Cancer Screening Program [8]
in Indonesia”, Journal of Global Oncology, Vol. 4/Supplement 2, https://doi.org/10.1200/jgo.18.21100.
World Cancer Research Fund/American Institute for Cancer Research (2018), Diet, nutrition, physical [1]
activity and breast cancer, World Cancer Research Fund/American Institute for Cancer Research,
https://www.wcrf.org/sites/default/files/Breast-cancer-report.pdf.
Yeung, M. et al. (2019), “Hong Kong female’s breast cancer awareness measure: Cross-sectional survey”, [13]
World Journal of Clinical Oncology, Vol. 10/2, pp. 98-109, https://doi.org/10.5306/wjco.v10.i2.98.
Zhang, M. et al. (2021), “Breast Cancer Screening Rates Among Women Aged 20 Years and Above — [12]
China, 2015”, China CDC Weekly, Vol. 3/13, pp. 267-273, https://doi.org/10.46234/ccdcw2021.078.
Figure 7.7. Mammography screening in women aged 50-69 within the past two years, 2020 (or
nearest year)
2019 2020
% of women aged 50-69
80
71 67 70
63 62
60 55 55
50 47 45
39
40
27 26
20 11
0
New Zealand ¹ Korea ¹ OECD36/28 Australia ¹ Asia Pacific-H Japan ² Singapore ¹ Hong Kong China ² Brunei
(China) ² Darussalam ²
Figure 7.8. Breast cancer five-year net survival, women diagnosed during 2000-04 and 2010-14
Confidence interval 2010-14 2000-04 2010-14
Age-standardised five-year net survival (%)
100
90 89 88 87 86 84
80 83 83 80 76 72 69 66 65
60
40
20
0
Note: For all countries, 95% confidence intervals for women diagnosed during 2010-14 are represented by grey areas. For Hong Kong (China),
Mongolia and Malaysia the estimate in light blue is for 2005-09. 1. Data represent coverage of less than 100% of the national population.
2. Survival estimates are considered less reliable. See Allemani et al. (2018) for more information.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/oqtixz
35
41.0
30
20.7
19.3
19.0
18.9
18.8
17.8
25
15.8
15.3
14.1
13.8
13.8
13.3
13.3
12.7
12.5
12.0
11.7
20
11.0
10.3
10.0
10.0
9.9
9.6
9.3
15
7.6
6.4
3.9
10
5
0
References
Allemani, C. et al. (2018), “Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): [6]
analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322
population-based registries in 71 countries”, The Lancet, Vol. 391/10125, pp. 1023-1075,
https://doi.org/10.1016/S0140-6736(17)33326-3.
IARC (2022), Cancer Over Time, International Agency for Research on Cancer, Lyon, [4]
https://gco.iarc.fr/overtime/en.
IARC (2022), Cancer Today, International Agency for Research on Cancer, Lyon, https://gco.iarc.fr/today/. [3]
Ministry of Health, Labour and Welfare (2022), HPV vaccine ni kansuru Q&A, [5]
https://www.who.int/teams/noncommunicable-diseases/surveillance/data/cancer-profiles.
Figure 7.10. Vaccination coverage for human papillomavirus vaccine, complete schedule, females
by age 15 (15HPVc), 2018-20
2018 2019 2020
% of girls aged 15
100
90
80
70
60
50
40
30
20
10
86 88 89 82 96 83 54 59 74 77 75 72 58 66 62 58 58 58 47 64 53 56 1 1
0
Brunei Malaysia Asia Pacific-H Australia New Zealand OECD27/27/19 Korea Fiji Singapore
Darussalam 5/5/3
Figure 7.11. Cervical cancer: Age-standardised five-year net survival, 2000-04 and 2010-14
Confidence interval 2010-14 2000-04 2010-14
Age-standardised five-year net survival (%)
100
77 71 69 68 67 66
80 60 59 57 54
60
66 66 63
40
20
0
Note: For all countries, 95% confidence intervals for women diagnosed during 2010-14 are represented by grey areas. For Hong Kong (China)
and Malaysia the estimate in light blue is for 2005-09. 1. Data represent coverage of less than 100% of the national population. 2. Survival
estimates are considered less reliable. See Allemani et al. (2018[6]) for more information.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/ewla1h
20
14.4
14.4
11.6
11.4
11.1
15
10.1
8.8
8.3
7.9
7.4
6.7
6.7
10
6.5
5.8
5.7
5.3
4.9
4.0
3.4
3.3
3.0
2.9
2.9
2.0
1.8
1.5
5
0
References
CONCORD Working Group (2022), “Does the morphology of cutaneous melanoma help explain the [5]
international differences in survival? Results from 1,578,482 adults diagnosed during 2000‐2014 in 59
countries ( <scp>CONCORD</scp> ‐3)”, British Journal of Dermatology,
https://doi.org/10.1111/bjd.21274.
Di Carlo, V. et al. (2020), “Trends in short-term survival from distant-stage cutaneous melanoma in the [6]
United States, 2001-2013 (CONCORD-3)”, JNCI Cancer Spectrum, Vol. 4/6,
https://doi.org/10.1093/jncics/pkaa078.
IARC (2022), Cancer Over Time, International Agency for Research on Cancer, Lyon, [2]
https://gco.iarc.fr/overtime/en.
IARC (2022), Cancer Today, International Agency for Research on Cancer, Lyon, https://gco.iarc.fr/today/. [1]
Miyawaki, Y. et al. (2022), “Impact of the coronavirus disease 2019 pandemic on first-visit patients with [4]
oesophageal cancer in the first infection wave in Saitama prefecture near Tokyo: a single-centre
retrospective study”, Japanese Journal of Clinical Oncology, Vol. 52/5, pp. 456-465,
https://doi.org/10.1093/jjco/hyac002.
Okuyama, A. et al. (2022), “Impact of the COVID-19 pandemic on the diagnosis of cancer in Japan: an [3]
observational study of hospital-based cancer registries data”, The Lancet Oncology, Vol. 23, p. S22,
https://doi.org/10.1016/s1470-2045(22)00421-1.
Figure 7.13. Oesophageal cancer five-year net survival, patients diagnosed during 2000-04 and 2010-14
Confidence interval 2010-14 2000-04 2010-14
Age-standardised five-year net survival (%)
100
80
60
36 31 30
40 24 24
17 16 15 15 14
20 7 4
0
Note: For all countries, 95% confidence intervals for patients diagnosed during 2010-14 are represented by grey areas. For Malaysia the estimate
in light blue is for 2005-09. 1. Data represent coverage of less than 100% of the national population. 2. 2010-14 survival estimate for Malaysia
and 2000-04 survival estimate for India are not age-standardised. 3. Survival estimate for 2000-04 is considered less reliable.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/w0eh4c
Figure 7.14. Melanoma five-year net survival, patients diagnosed during 2000-04 and 2010-14
Confidence interval 2010-14 2000-04 2010-14
Age-standardised five-year net survival (%)
100
80 93 92 60
83 50
60 75 69 40
62 60
40
20 30
0
1. Data represent coverage of less than 100% of the national population. 2. Survival estimates are not age-standardised. 3. Survival estimates
are considered less reliable.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/qb2eyx
Figure 7.15. Childhood leukaemia five-year net survival, children diagnosed during 2000-04 and 2010-14
Confidence interval 2010-14 2000-04 2010-14
Age-standardised five-year net survival (%)
100
91 91 89 89 88
80 84 84 82
76
69 66
60 58
40
20
0
Note: Malaysia the estimate in light blue is for 2005-09 and for India, the estimate in dark blue is for 2005-09. 1. Data represent coverage of less
than 100% of the national population. 2. Survival estimates are considered less reliable. 3. Survival estimates are not age-standardised.
Source: CONCORD programme, London School of Hygiene and Tropical Medicine.
StatLink 2 https://stat.link/b0z2gt
Bangladesh
Brunei Darussalam
Cambodia
China
Macau (China)
Malaysia
Myanmar
Nepal
Singapore
Sri Lanka
Table A B.2. Share of the population aged 65 and over, 1980 to 2025
1980 1990 2000 2010 2020 2025
Australia 9.6 11.1 12.4 13.6 16.2 17.9
Bangladesh 3.4 3.5 3.8 4.4 5.6 6.7
Brunei Darussalam 2.8 2.6 2.9 3.4 5.5 7.4
Cambodia 3.0 3.0 3.1 3.6 5.3 6.8
China 4.4 5.3 6.9 8.6 12.6 14.9
Democratic People’s Republic of Korea 3.4 4.4 6.4 9.5 11.1 13.0
Fiji 2.6 2.8 3.2 4.2 5.5 6.5
Hong Kong (China) 6.4 8.6 11.2 13.3 18.8 23.3
India 4.0 4.1 4.5 5.1 6.7 7.6
Indonesia 3.7 4.0 5.0 5.9 6.7 7.5
Japan 9.3 12.4 17.8 23.6 29.6 30.4
Korea 3.8 4.9 7.1 11.0 15.8 20.3
Lao People’s Democratic Republic 3.3 3.4 3.5 3.9 4.3 4.9
Macau (China) 7.5 6.6 7.3 7.1 11.7 15.1
Malaysia 3.3 3.7 4.1 5.1 7.0 8.4
Mongolia 4.8 3.8 3.4 3.8 4.3 5.4
Myanmar 4.1 4.4 4.9 5.2 6.5 7.5
Nepal 3.4 3.6 3.8 4.7 6.0 6.3
New Zealand 9.8 11.1 11.7 13.0 15.6 17.6
Pakistan 3.4 3.5 3.5 3.7 4.2 4.5
Papua New Guinea 1.1 1.8 2.3 2.6 3.0 3.5
Philippines 3.3 3.3 3.8 4.3 5.2 6.0
Singapore 4.9 5.6 6.3 7.2 13.2 18.1
Solomon Islands 3.2 3.2 3.3 3.4 3.5 3.6
Sri Lanka 4.9 6.1 7.1 7.6 10.8 12.7
Thailand 3.4 4.3 6.1 8.8 13.9 17.5
Viet Nam 5.5 5.6 6.2 6.5 8.4 10.4
Table A B.3. Crude birth rate, per 1 000 population, 1980-85 to 2015-20
1980-85 1990-95 2000-05 2010-15 2015-20
Australia 15.6 14.7 12.8 13.3 12.9
Bangladesh 42.2 33.0 26.0 20.2 18.4
Brunei Darussalam 30.7 28.3 19.2 16.7 15.0
Cambodia 50.6 38.0 26.5 24.5 22.7
China 21.6 17.9 12.5 12.6 11.9
Democratic People’s Republic of Korea 21.7 20.7 16.8 14.0 13.9
Fiji 33.1 28.1 24.0 20.7 21.5
Hong Kong (China) 15.3 12.4 8.4 10.5 11.1
India 35.5 30.0 25.3 20.0 18.0
Indonesia 31.7 24.4 22.0 20.2 18.2
Japan 12.8 9.8 8.9 8.4 7.5
Korea 20.1 16.0 10.5 8.9 7.4
Lao People’s Democratic Republic 42.9 41.5 29.7 25.5 23.8
Macau (China) 21.2 15.1 7.5 11.3 11.0
Malaysia 31.1 27.2 19.4 17.2 16.8
Mongolia 38.2 27.5 18.9 26.0 24.4
Myanmar 34.4 25.7 24.3 18.7 17.7
Nepal 41.2 37.2 29.7 20.9 20.0
New Zealand 15.8 16.6 14.2 13.7 12.6
Pakistan 42.1 38.2 30.3 29.7 28.5
Papua New Guinea 38.3 34.5 33 28.8 27.2
Philippines 35.7 31.9 28.8 24.1 20.6
Singapore 17.0 17.6 11.3 9.3 8.8
Solomon Islands 42.4 38.8 35.1 30.8 32.7
Sri Lanka 25.8 19.8 18.6 16.4 16.0
Thailand 24.2 18.2 13.6 11.3 10.5
Viet Nam 31.4 26.7 16.9 17.4 16.9
Table A B.4. Fertility rate, live births per woman aged 15-49, 1980-85 to 2015-20
1980-85 1990-95 2000-05 2010-15 2015-20
Australia 1.9 1.9 1.8 1.9 1.8
Bangladesh 6.0 4.1 2.9 2.2 2.1
Brunei Darussalam 3.8 3.1 2.0 1.9 1.8
Cambodia 6.4 5.1 3.4 2.7 2.5
China 2.6 2.0 1.6 1.6 1.7
Democratic People’s Republic of Korea 2.8 2.3 2.0 2.0 1.9
Fiji 3.8 3.4 3.0 2.6 2.8
Hong Kong (China) 1.7 1.2 1.0 1.2 1.3
India 4.7 3.8 3.1 2.4 2.2
Indonesia 4.1 2.9 2.5 2.5 2.3
Japan 1.8 1.5 1.3 1.4 1.4
Korea 2.2 1.7 1.2 1.2 1.1
Lao People’s Democratic Republic 6.4 5.9 3.9 2.9 2.7
Macau (China) 2.1 1.4 0.8 1.2 1.2
Malaysia 4.0 3.4 2.5 2.1 2.0
Mongolia 5.8 3.3 2.1 2.8 2.9
Myanmar 4.7 3.2 2.9 2.3 2.2
Nepal 5.6 5.0 3.6 2.3 1.9
New Zealand 2.0 2.1 1.9 2.0 1.9
Pakistan 6.4 5.7 4.2 3.7 3.6
Papua New Guinea 5.5 4.7 4.4 3.8 3.6
Philippines 4.9 4.1 3.7 3.1 2.6
Singapore 1.7 1.7 1.3 1.2 1.2
Solomon Islands 6.4 5.5 4.6 4.1 4.4
Sri Lanka 3.2 2.4 2.3 2.1 2.2
Thailand 2.9 2.0 1.6 1.5 1.5
Viet Nam 4.6 3.2 1.9 2.0 2.1
9HSTCQE*eccefc+